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1. INTRODUCTION 
 
1.1  Hypothalamo-pituitary-gonadal axis and the female cattle reproductive cycle 
Reproductive functions in the bovine species are governed, as in all mammalian species, by the 
hypothalamus-pituitary-gonadal (HPG) axis. The HPG axis is composed of three anatomically and 
functionally distinct structures, that interact trough a complex system of positive and negative 
hormonal feedback loops. In the female it is specifically named the hypothalamus-pituitary-ovarian 
(HPO) axis. 
In 1910 a work from Crowe linked for the first time the pituitary gland function to the 
development of genital organs (Crowe et al., 1910). Further studies have been developed till 1926 
when Smith showed that the ovarian atrophy after removal of the hypophysis was reversed by 
pituitary implants (Smith, 1926-A,B) and Zondek evoked precocious sexual maturation in immature 
animals with external implantation of anterior pituitary glands (Zondek, 1926). Thus confirming the 
pituitary-ovarian link hypothesis. 
It was first in 1929-1930 when Zondek proposed the idea that two hormones might be required 
for normal ovarian function (Zondek, 1929, 1930). It was after he showed that extracts from urine 
collected from postmenopausal women produced a predominant follicle-stimulating effect, whereas 
urine from pregnant women showed a strong luteinizing activity (Göretzlehner et al., 1978).  
Fevold and a co-worker proved the latest hypothesis isolating two crude pituitary hormones 
with distinct actions in the ovary of the rat (Fevold et al., 1931). The first, the follicle stimulating 
hormone (FSH), stimulated the ovarian follicular development and the luteinizing hormone (LH) 
which caused FSH-stimulated follicle to luteinize. 
It was many years later when Guillemin suggested that a higher centre in the brain controlled 
the secretion of gonadotropins from pituitary gland, proposing the hypothalamus-pituitary link 
(Guillemin, 1967). The existence of HPG axis was finally confirmed in early 1970s by Schally and 
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Guillemin when they elucidated the chemical structure of gonadotropin releasing hormone (GnRH) 
(Schally et al., 1971; Burgus et al., 1972). 
Nowadays, it is well well-known HPO is a complex neuroendocrine system regulated through 
several feedback loops using different chemical messengers such as neurotransmitters, hormones and 
growth factors. Figure 1 shows a schematic representation of the HPO axis. 
 
 
 
Figure 1 
Hypothalamic–pituitary–gonadal axis. The figure shows the complexity of posisitve and negative 
feedback system involved in the regulation of gonadotropin production and release. Loops and 
products are illustrated. (Duran-Pasten et al., 2013). 
 
GnRH modulates the activity of anterior pituitary gonadotropes, controlling FSH and LH 
synthesis and release. It has been demonstrated that while both LH and FSH are released from the 
gonadotrope in a basal manner independent of GnRH only the release of pulses of LH is totally 
dependent on pulsatile GnRH input, while the release of FSH is associated only with a small amount 
proportion of GnRH pulse (Kile et al., 1994; Padmanabhan et al., 1997; Clarke et al., 2002).  
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The GnRH, LH, and FSH synthesis and secretion are modulated by a complex feedback 
mechanisms of gonadal molecules. First of all, sex-steroids, inhibins and activins. Nevertheless, over 
the last decade a series of new gonadal proteins have been discovered, including Mullerian inhibiting 
substance (MIF), epidermal growth factor (EGF), transforming growth factor (TGF), and insulinlike 
growth factors (IGF-I and IGF-II). It has become evident that regulation of gonadal function and 
gametogenesis can no longer be explained solely by the effects of the sex-steroids and the two 
gonadotropins. 
 
1.2.  Molecular structure of bovine GnRH 
Gonadotropin-releasing hormone is the master hormone controlling the HPO axis and therefore 
female reproductive physiology. It belongs to a group of neuropeptides isolated as factors of 
hypothalamic origin (Schneider et al., 2006). There are currently 23 identified naturally occurring 
GnRH structural variants across the vertebrate species (Millar et al., 2004; Morgan et al., 2004). 
The hypothalamic form of GnRH is designated GnRH-I (Sealfon et al., 1997; Pawson et al., 
2005). It is a decapeptide synthesized from a 92 amino acid precursor. The GnRH-I signal peptide is 
composed of a 23 amino acid N-terminal peptide, the biological active decapeptide, a 3 amino acidic 
sequence of enzymatic cleavage and a 56 amino acid peptide named GAP (GnRH-associated-
peptide) at the C-terminal. The GnRH-I decapeptide with pyroglutamyl amino (N) and amidated 
carboxy (C) terminals has an identical amino acidic sequence in all mammalian species studied 
(Dellovade et al., 1998; Pei-San, 2006), while GnRH-I precursor is species-specific (Figure 2). Table 
1 reports the percentages of amino acid identity between the GnRH-I precursor of nine mammalian 
species in comparison with the bovine. 
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Bovine    MKPTPKLLAG LILLILCVVG CSGQHWSYGL RPGGKRNAEN VIDSFQEIAK EVDQPVEPKC 
Ovine     ////////// ////////// ///------- --------K- ---------- ---------- 
Bufalo    –E-------- ----T----- ---------- ---------- ---------- ---------- 
Equine    -E-I------ ----T----- --S------- --------D- L--------- --N--A--QR 
Pig       -E-I------ -L--T----- --S------- ---------- -------M-- --ARLA--QR 
Rabbit    -ELI------ -M--T---E- --S------- ---------- L------R-- --------QR 
Human     ---IQ----- ----TW--E- --S------- ------D--- L-------V- --G-LA-TQR 
Dog       -E-I---V-- -L--TF---S ---------- ---------H L------M-- -L---A--QH 
Rat       -ETI---M-A VV--TV-LE- --S------- -------T-H LV-----MG- -E--MA--QN 
Mouse     -ILKLMAGIL –LTVC-EG// --S------- -------TEH LVE----MG- ----MA--QH 
 
                   70         80         90 
Bovine    CGCIVHQSHS PLRDLKAALE SLIEEETGQR KI 
Ovine     ---------- ---------- ----////// // 
Bufalo    ---------- ---------- ---------- -- 
Equine    FE-T---PR- ------G--- ---------K -- 
Pig       FE-TA--PR- ------G--- ---------K T/ 
Rabbit    FE-TIL-PR- ---G--E--D ---------- -- 
Human     FE-TT--PR- ------G--- ---------K -- 
Dog       LE-TI-KPRP -----RG--- ---------K R- 
Rat       FE-T--WPR- -----RG--- R-----A--K -M 
Mouse     FE-T--WPR- -----RG--- ------AR-K –M 
 
 
 
Figure 2 
Amino acidic sequence of  pre-GnRH-I in 9 mammalian species compared to the  bovine 
GnRH-I precurosor. The green box highlight the ten identical amino acid of GnRH-I. 
 
 
Table 1 
Identity between GnRH-I sequence of  9 
mammalian species in respect of  bovine 
GnRH-I. 
 Number of different  
Amino acids 
    Identity 
  (%) 
Ovine               1         99 
Bufalo               2         98 
Equine              17         82 
Pig              21         77 
Rabbit              21         77 
Human              23         75 
Dog              26         72 
Rat              35         62 
Mouse              40         57 
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1.3.  Molecular structures of bovine FSH and LH 
FSH and LH together with thyroid stimulating hormone (TSH) and chorionic gonadotropin 
(CG) belongs to the glycoprotein hormone family which is structurally considered the most complex 
hormone family in animal kingdom (Dirnberger et al., 2001). FSH, LH and TSH are produced and 
secreted by the anterior pituitary gland, while CG is produced by placental trophoblasts only in 
primates and equids. 
These are all heterodimers consisting of a common α-subunit non-covalently bound to a b-
subunit. Within a given animal species the α-subunit has an identical amino acid sequences in all four 
glycoprotein hormones as is encoded by the same gene; while the b-subunit arise from different 
genes and so is unique and determine the hormone biological and immunological activity (Ulloa-
Aguirre et al., 2001-A). 
Each subunit forms intra-chain disulfides bridges and present glycosylation sites which makes 
the hormone produced and secreted not as a single structure but as a mixture of glycosylation 
isoforms (Szkudlinski et al., 1995).  
 
1.3.1  FSH and LH differently glycosylated isohormone 
Carbohydrates are an important structural component of the gonadotropins, comprising nearly 
20-30% of the hormone mass. Glycosylation represent the most pronounced and most complex form 
of protein post-translational modification (Geyer et al., 2006). It involves a complex biosynthetic 
pathways beginning in the rough endoplasmic reticulum (RER) continuing through the Golgi 
apparatus until the mature hormone is transported to secretory granules (Ulloa-Aguirre et al., 2001-
A). There are mainly two types of protein glycosylation: N-glycosylation and O-glycosylation. In 
pituitary gonadotropins (FSH and LH), we only find the N-glycosylation type in all mammalian 
species, with the exception of equine LH (see section 1.3.3.1). 
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Figure 3 shows a summary of the biosynthetic pathway for N-linked oligosaccharides. During 
the N-glycosylation the common core, from a lipid-linked precursor (dolichol) is transferred to the 
amide group of asparagines within an Asn-X-Ser/Thr motif, where X is any amino acid apart from 
proline (Geyer et al., 2006; Ulloa-Aguirre et al., 2001-A). This precursor is further modified by α-
glucosidase I and II removing terminal glucose residues and a 2-mannosidases removing one 
mannose residue. A common core is so generated composed by two N-acetyl glucosamine (GlcNac) 
residues linked to three mannose. After dimer formation and trimming of glucose and mannose 
residues to a Man5GlcNac2 in RER and cis-Golgi apparatus further processing occurs in the medial 
and trans-Golgi involving several enzymes, such as N-acetyl galactosamine (GalNac) transferase, N-
acetyl glucosamine transferase, syaliltransferase, etc..., till mature oligosaccharides is formed (Ulloa-
Aguirre et al., 2001-A). 
Figure 3 
Summary of the biosynthetic pathway for N-linked oligosaccharides. Some key steps are shown, 
starting with en bloc transfer of the common core from a lipid-linked precursor (dolichol). Steps 
include: oligosaccharyltransferase-catalyzed transfer of dolichol-linked Glc3Man9GlcNAc2 
oligosaccharide to aspargine at glycosylation site–Asn-Xaa-Thr/Ser (step a); _-glucosidase I and 
II remove terminal glucose residues, endoplasmic reticulum (RER) _-1, 2-mannosidase removes 
one mannose residue, and Golgi _-mannosidase I removes an additional three mannose residues 
(step b); N-acetylglucosamine-transferase adds N-acetylglucosamine, forming precursor for a 
structure having only one completed branch (step c), or leading to continued processing in which 
Golgi _-mannosidase II removes two mannose residues (step d), and N-acetylglucosamine-
transferase II adds a second N-acetylglucosamine residue (step e), leading to further processing 
(steps f and g) (Ullua-Aguirre et al., 2001-A). 
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Oligosaccharides structure of glycoprotein hormones have been shown to play an essential role 
in many of the functional characteristic of the hormones. They determine the maintenance of protein 
folding, subunit assembly, conformational maturation and heterodimer secretion, as well as metabolic 
clearance, interaction with its cognate receptor and signal transduction. (Fiete et al., 1991; Bousfield 
et al., 1996; Ulloa-Aguirre et al., 2001-B, Perrera-Marìn et al., 2007). In fact deglycosylated 
glycoproteins by chemical or enzymatic procedures are rapidly cleared from the circulation and are 
practically inactive in vivo when compared to the corresponding intact variant. Oligosaccharides on 
the β-subunit play a major role in determining the metabolic clearance rate of gonadotropins, while 
glycosilation of the α-subunit is essential to activation of the receptor/signal transducer (G-protein) 
system and the subsequent biological response. In fact the removal of α-subunit oligosaccharides 
result in an increased capacity to bind the receptor, but a significantly reduced signal transduction 
capability (Ulloa-Aguirre et al., 2001-B). 
Glycoprotein hormone FSH and LH must be viewed as a heterogeneous mixture of closely 
related variants, so called isoforms. This polymorphism occurs due to variations in the structure of 
the oligosaccharides (Baenzinger et al., 1988; Manzella et al., 1996; Ulloa-Aguirre et al., 1999, 
2001a,b; Dias, 2001), which affects the physicochemical characteristics and biological and 
immunological activities of the hormone. 
The asparagine-linked oligosaccharides on the pituitary glycoprotein hormones LH and FSH, 
consist of a heterogeneous array of neutral, sulfated, sialylated, and sulfated/sialylated structures. The 
glycosilation differences are both qualitative and quantitative and usually involve the content of sialic 
acid (Sia), N-acetil-galactosamine sulphate (SO4-4GalNAc), galactose (Gal), mannose (Man) and N-
acetilglucosamine (GlcNAc). The sulfated oligosaccharides consist of mono- (S-1) and di- (S-2) 
sulfated structures containing the characteristic peripheral sequence SO4-4GalNAcb1, 
4GlcNAcbl,2Manα. The sialylated oligosaccharides consist of a wide array of structures differing in 
number (1 (N-l), 2 (N-2), and 3 (N-3)) and linkage (α2,3 versus α2,6) of sialic acid moieties as well 
as underlying oligosaccharide structure (Stockell et al., 1992; Green et al., 1988-A,B). The major 
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difference between the LH and FSH oligosaccharides is the significantly different distributions of 
sulfated and sialylated oligosaccharides. Bovine LH for example only contains sulfated 
oligosaccharides, with 78% of monosulfated branches and 22% of disulfated branches, while bFSH 
contains both sialylated to sulfated oligosaccharides, with sialylated structures dominating. Sialylated 
oligosaccharides are also heterogeneous with respect to sialic acid linkage (α2,3 versus α2,6), and 
substitution (i.e.: N-acetyl- and N-glycolyl-neuraminic). 
Interestingly, there are not only hormone- but also animal species-specific differences in the 
types and distributions of sulfated, sialylated, and sulfated/sialylated structures. The differences are 
both qualitative and quantitative. For example, relative distribution of sialylated, sulfated and neutral 
Asn-linked oligosaccharides in human-LH is: 58%, 49% and 0%, and in bovine-LH is: 0%, 67% and 
33%. The relative distribution of the same sugars in human FSH is: 88%, 7% and 5% and 56%, 13% 
and 31% in bovine FSH (Green et al., 1988-A,B). Furthermore, it has been shown that bovine FSH 
carries both N-acetyl- and N-glycolyl-neuraminic acids (Neu5GC and Neu5Ac) (Borromeo et al., 
2004), while Neu5Gc is absent in primates and chicken, due to the lack of a functional CMP-
Neu5Ac-hydroxylase (Chenu et al., 2003; Varki, 2001). This adds further evidence to the role of 
sugars in determining FSH species-specificity. 
The functional significance of this diversity of isoforms is not yet fully understood. Sialic acid 
seems to be the major determinant for the circulatory stability of glycoprotein hormones. This sugar 
content and the number of exposed terminal galactose residues is essential in determining the 
hormone survival in circulation. In fact the exposure of terminal galactose residues dramatically 
increases the rate of glycoprotein clearance from plasma through a mechanism that involves 
hepatocites receptors for the asialo galactose-terminal complex molecules. In contrast terminal 
GalNAc-4-sulfate residues or oligosaccharides bearing terminal mannose or GlcNAC accelerate the 
molecule clearance by specific receptors present in hepatic endothelial and Kupffer cells (Fiete et al., 
1991, Fiete et al., 1997, Dirnberger 2001).  As a consequence, heavily sialylated glycoproteins, such 
as FSH, have longer plasma half life and higher in vivo bioactivity, despite lower in vitro bioactivity, 
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(Dirnberger et al., 2001; Szkudlinski et al., 1995), than less sialylated molecules (e.g. LH) and, 
although the mixture of charge isoforms in serum contains most of the isoforms detected in pituitary 
extract (for example the spectrum of the sialylation variants of human FSH extracted from the 
anterior pituitary includes approximately 20 isoforms exhibiting both basic to very acid pH values), 
the strongly acidic isoforms predominate due to the rapid clearance of their less sialylated 
counterparts (Ulloa-Aguirre et al., 2001-B).  
Several studies performed by Bogdanove and associates showed that androgen treatment 
altered the B/I ratio, (B) bioactivity, (I) immunoreactivity, suggesting for the first time that changes 
in the endocrine milieu could modify the gonadotropin structure. Further studies detected that the 
molecular weight of pituitary gonadotropins differed depending on the endocrine status of the donor 
animal (Bogdanove et al., 1974; Peckham et al., 1973). Subsequently, significant variations in the 
relative abundance of intrapituitary and circulating gonadotropin glycoforms have been documented 
in several physiologic conditions characterized by profound changes in the endocrine environment to 
which the pituitary is exposed, including puberty (Phillips et al., 1997; Padmanabhan et al., 1992), 
the menstrual cycle (Padmanabhan et al., 1988; Wide et al., 1993; Anobile et al., 1998), and 
senescence (Wide, 1985; Wide, 1989; Anobile et al., 1998). For example, intrapituitary LH and/or 
FSH are more acidic/sialylated in males and in older individuals of both sexes, and circulating 
gonadotropins in the postmenopausal state (a physiologic estrogen- deprived condition) are more 
sialylated and circulate for longer periods of time than those from women at reproductive age (Ulloa-
Aguirre et al., 2001-B). Several studies have also detected the occurrence of significant changes in 
the relative distribution of the glycosylated variants of serum LH and FSH throughout the menstrual 
cycle, with greater proportions of less acidic forms released during midcycle than in the early-, mid-
follicular, and luteal phases.  
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1.3.2  Bovine glycoprotein hormone common α-subunit 
In Figure 4 the bovine α-subunit amino acid sequence is compared to the α-subunits from 18 
mammals. Table 2 reports the pair-wise comparisons (bovine vs other species) for amino acid 
sequences of these animal species.  
 
            10         20         30         40         50         60 
BOVINE   FPDGEFTMQG CPECKLKENK YFSKPDAPIY QCMGCCFSRA YPTPARSKKT MLVPKNITSE 
BUFFALO  ---------- ---------- ---------- ---------- ---------- ---------- 
OVINE    ---------- ---------- ---------- ---------- ---------- ---------- 
PIG      ---------- ---------- ----LG---- ---------- ---------- ---------- 
GOAT     ------M--- ---------- ---------- ---------- ---------- ---------- 
DEER     ------M--- ---------- ---------- ---------- ---------- ---------- 
DOG      ---------- ---------- ----LG---- ---------- ---------- ---------- 
RABBIT   ------A--- ---------- ----LG---- ---------- ---------- ---------- 
TIGER    ---------- ---------- ----LG--V- ---------- ---------- ---------- 
CAT      ---------- ---------- ----LG---- ---------- ---------- ---------- 
KANGAROO ------I--- ---------- ----LG---- ---------- ---------- ---------- 
RAT      L---D-II-- ---------- ----LG---- ---------- ---------- ---------- 
MOUSE    L---D-II-- ---------- ----LG---- ---------- ---------- ---------- 
WHALE    --B-Z---Z- --Z----ZB- ----LG---- Z--------- ---------- ---------Z 
DONKEY   -------T-D -------K-- ----LGV--- ---------- ---------- ---------- 
MACACO   ---------D -----PR--- F----G---- ---------- ----V----- ---Q--V--- 
UISTITI  L------AEE ---------- ---RLGS--- ---------- ----L--Q-- ------V--- 
HORSE    -------T-D ------R--- --F-LGV--- --K------- -------R-- ---------- 
HUMAN    AP-////V-D ----T-Q--P F--Q-G---L ---------- ----L----- ---Q--V--E 
 
                   70         80         90     96 
BOVINE     ATCCVAKAFT KATVMGNVRV ENHTECHCST CYYHKS 
BUFFALO    ---------- ---------- ---------- ------ 
OVINE      ---------- ---------- ---------- ------ 
PIG        ---------- -------A-- ---------- ------ 
GOAT       ---------- ----T----- ----D----- ------ 
DEER       ---------- ---------- ----D-H--- ------ 
DOG        ---------- -------AK- ---------- ------ 
RABBIT     ---------- -------AK- ---------- ------ 
TIGER      ---------- -------AK- ---------- ------ 
CAT        ---------- -------AK- ---------- --H--I 
KANGAROO   ---------- -----D--KI ---------- ------ 
RAT        ---------- -------A-- ---------- ------ 
MOUSE      ---------- -------A-- ---------- ------ 
WHALE      ---------- ------BA-- Z---Z----- ------ 
DONKEY     ---------I RV-L---I-L ----Q-Y--- --H--I 
MACACO     S------SL- RVM---S--- ---------- -----F 
UISTITI    S-------Y- -------I-- ---------- --H--F 
HORSE      S--------I RV-----IKL ----Q-Y--- --H--I 
HUMAN      S------SYN RV----GFK- ----A----- ------ 
 
Figure 4 
Glycoprotein hormone α-subunit amino acid sequence of 18 mammalian species in 
comparison to bovine amino acid sequence. Cys residues forming the four intra-chain 
disulfides bridges are highlighted in yellow. 
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Table 2 
Identity percentage between glycoprotein hormone α-
subunit of 18 different mammalian species in comparison 
to bovine α-subunit. 
Species N°aa different Identity percentage 
(%) 
Buffalo 0 100 
Ovine 0 100 
Pig 3 97 
Goat 3 97 
Deer 3 97 
Dog 4 96 
Rabbit 5 95 
Tiger 5 95 
Cat 6 94 
Kangaroo 6 94 
Rat 7 93 
Mouse 7 93 
Whale 14 85 
Donkey 16 83 
Macaco 16 83 
Uistitì 16 83 
Horse 20 79 
Human 25 74 
 
 
In general, the glycoprotein hormone α-subunit amino acid sequence is specie-specific. 
Nonetheless, the α-subunit of bovine, ovine and buffalo have the same sequence. Furthermore, all the 
ten cysteine residues, forming four intra-chain disulfides bridges, are conserved among mammalian 
species, suggesting that the glycoprotein hormone α-subunit have similar tridimensional structure in 
different species (see section 1.3.4). 
In the bovine species, the glycoprotein hormone common α-subunit is encoded by a gene 
composed of four exons and three introns (gene ID:280749). The gene is localized on chromosome 9 
and has 22 kb dimension.  
The mature protein is composed of 96 amino acids, with five disulphide bridges at Cys11-Cys35, 
Cys14-Cys64, Cys32-Cys86, Cys36-Cys88, Cys61-Cys91 positions and two N-glycosidic linked 
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oligosaccharides, at Asn56 and Asn82. The calculated molecular weight (Mr) is 10791.5 and the 
isoelectric point (pI) 8.70. However, subunit glycosylation determines a significant difference 
between the Mr and pI theoretical values and experimental data (Ulloa-Aguirre et al., 2001-A). 
 
1.3.3  Bovine glycoprotein hormone b-subunits 
As mentioned before the β-subunit is unique for each hormone determining it’s biological 
activity. In Figure 5 the b-subunit amino acid sequences of bovine LH, FSH and TSH are compared.  
Table 3 reports the pair-wise comparisons for amino acid sequences of these three bovine hormone b-
subunits.  
 
              S1              S2  S3        S4  S5                     S6  
bLHb  SRGPLRPLCQ PINATLAAEK EACPVCITFT TSICAGYCPS MKRVLPVIL/ /PPMPQRVCT  
bFSHb ////////CE LTNITITVEK EECGFCISIN TTWCAGYCYT RDLVYRDPA/ /RPNIQKTCT  
bTSHb ///////FCI PTEYMMHVER KECAYCLTIN TTVCAGYCMT RDVNGKLFLP KYALSQDVCT  
 
            S7               S8 S9  S10     S11         S12 
bLHb   YHELRFASVR LPGCPPGVDP MVSFPVALSC HCGPCRLSST DCGGPRTQPL ACDHPPLPDI LFL n.121 
bFSHb  FKELVYETVK VPGCAHHADS LYTYPVATEC HCSKCDSDST DCTVRGLGPS YCSFREIKE      n.109 
bTSHb  YRDFMYKTAE IPGCPRHVTP YFSYPVAISC KCGKCNTDYS DCIHEAIKTN YCTKPQKSY      n.112 
 
Figure 5 
Amino acid sequence of the β-subunits of bovine LH, FSH e TSH, aligned to mixmimise 
identity. Yellow box highlight the Cys residues forming 12 intrachain disulfides bridges (S1-S12). 
 
 
 
Tabel 3 
Number of amino acid identitity between b-subunits of bovine LH, 
FSH and TSH and identity percentage respect to LHb sequence. 
Hormone Conserved aa Sequence identity 
(%) 
LHb  vs FSHb vs TSHb 25 22% 
LHb  vs FSHb (25 +13)  = 38 31% 
LHb  vs TSHb (25 + 6)  = 31 26% 
FSHb vs TSHb (25 + 8)  = 33 30% 
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Despite the low sequence homology (around ~30%) all twelve cysteine residues forming six 
intra-chain disulfides bridges, are conserved, suggesting that β-subunit tridimensional structure is 
very similar in the three pituitary glycoprotein hormones (see section 1.3.4). 
The bFSH β-subunit contains two N-linked oligosaccharides while the bLH β-subunit only 
contains one N-linked oligosaccharide. 
 
1.3.3.1  Bovine LH b-subunit 
In the bovine species, the LH b-subunit (bLHb) is encoded by a gene composed of three exons 
and two introns (ID: 280839). The gene is localized on chromosome 18 and is rather short, more or 
less 1,3 kb. 
The gene encode for a sequence of 121 amino acids with six disulphide bridges at Cys9-Cys57, 
Cys23-Cys72, Cys26-Cys110, Cys34-Cys88, Cys38-Cys80, Cys83-Cys100 and one glycosilation site (N-
glycosidically linked oligosaccharide) at Asn13. The theoretical Mr is 12972,4 and pI 8,30. As the b-
subunit is glycosylated these theoretical Mr are different from experimental values. 
In Figure 6 the bLHb amino acid sequence is compared to the bLHb from 14 different mammal 
species. Table 4 reports the pair-wise comparisons (bovine vs other species) for amino acid 
sequences of these species. 
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                  10         20         30         40         50         60         70 
BOVINE    SRGPLRPLCQ PINATLAAEK EACPVCITFT TSICAGYCPS MKRVLPVILP PMPQRVCTYH ELRFASVRLP 
BUFFALO   ---------- ---------- ---------- ---------- ---------- ---------- ---------- 
GOAT      ---------- ---------- ---------- ---------- ---------- ---------- ---------- 
SHEEP     ---------- ---------- ---------- --------L- ---------- ---------- ---------- 
PIG       ---------R ---------N ---------- ---------- -V----AA-- -V--P----R --S---I--- 
CAT       --E------R ---------N ------V--- -T-------- -M----AA-- -V--P----R ---------- 
TIGER     ---------R ---------N ------V--- -T-------- -M----AA-- -V--P----R ---------- 
DOG       ---------R ---------N ---------- -T-------- -V----AA-- -V--P----- --H---I--- 
MOUSE     ---------R –V-------N –F-------- ---------- -V----AA-- -V--P----R --A------- 
RABBIT  QAP--------R –V-------N ---------- ---------- -V----AA-- -V--P----R ------I--- 
RAT       ---------R –V-------N –F-------- ---------- -V----AA-- -V--P----R ---------- 
WHALE     P--------R --------ZB Z--------- ---------- -V----AA-- -V-ZP----R Z-----I--- 
HUMAN     --E----W-H ----I--V-- -G------VN –T-------T -M---QAV-- -L--V----R DV--E-I--- 
DONKEY    ---------R ---------- ----I----- --------R- -V--M-AA-- -I--P----R ----G-I--- 
HORSE     ---------R ---------- ----I----- ---------- -V--M-AA-- AI--P----R ------I--- 
                 
                    80         90        100        110         121 
BOVINE     GCPPGVDPMV SFPVALSCHC GPCRLSSTDC GGPRTQPLAC DHPPLPDILFL 
BUFFALO    ---------- ---------- ---------- ---------- ----------- 
GOAT       ---------- ---------- ---------- ---------- ----------- 
SHEEP      ---------- ---------- ---------- ---------- ----------- 
PIG        --------T- ---------- -------S-- ----A----- -R-L--GL--- 
CAT        --------V- --------R- -------S-- ----A----- -R----GL--- 
TIGER      --------V- --------R- -------S-- ----A----- -R----GLP-- 
DOG        ---------- --------R- ------NS-- ----A-S--- -R-L--GL--- 
MOUSE      --------I- --------R- -------S-- -------M-- -L-H--GL–L- 
RABBIT     --------E- --------R- -------S-- ----A----- -L-H--GL--- 
RAT        --------I- --------R- -P-----S-- -------MT- -L-H--GL-LF 
WHALE      ------B--- ---------- -------SB- -PG-AZ---- BRS-R-GL 
HUMAN      ---R----V- --------R- ----RS---- ---KDH--T- ---Q-SGL---      130        140       149 
DONKEY     ---------- ---------- -----KT--- ----DH---- APQTSSSCKDP PSQPLTSTS TPTPGASRRS SHPLPIKTS 
HORSE      ---------- ---------- ---QIKT--- -VF-D----- APQASSSSKDP PSQPLTSTS TPTPGASRRS SHPLPIKTS 
 
Figure 6 
LH β-subunit amino acid sequence of 14 mammalian species compared to bovine LH β-subunit. 
Cys residues forming the six intrachain disulfides bridges of the β-subunit are highlighted in yellow. 
 
 
Table 4 
Identity between LH β-subunit of 14 different mammalian 
species in comparison to bovine LH β-subunit 
Specie N°aa differing Identity  
(%) 
Buffalo 0 100 
Goat 0 100 
Ovine 1 99 
Pig 17 86 
Cat 18 85 
Tiger 18 85 
Dog 19 84 
Mouse 20 83 
Rabbit 21 83 
Rat 22 82 
Whale 27 78 
Human 34 72 
Donkey 55 55 
Horse 57 53 
17 
 
 
The sequences of bovine, buffalo and goat bLHb are identical and differ from sheep LHb at 
one residues. The sequences of any of these LHb differ from the other terrestrial mammalian 
sequences by 17-22 residues, and from that of human LHb by 34 residues.  
It is interesting to notice that equine and donkey LHb, contain a 28 amino acid peptide at the C-
terminal responsible of the low percentage of identity with the other mammalian species (total of 149 
amino acid sequence vs 121 of all mammalian species). Moreover, the additional 28 amino acid 
peptide at C-terminal is reach of glycosylated Ser residues making the equids LH (eLH) the only LH 
with O-glycosidically linked oligosaccharides (Bousfield., 2001; Galet et al., 2009). 
This particular eLHβ structure is very similar to the β-subunit of the chorionic gonadotropin 
(CGb). In fact both human CGβ and equine CGβ are formed of a 145-149 aminoacidic sequence and 
contains O-glycosidically linked oligosaccharides at their C-terminals (Fares, 2006; Galet et al., 
2009).  
The longer β-subunit sequence and the presence of O-linked oligosaccahrides are responsible 
of the considerably longer half life of the CG (about 36 h) compared to LH (30 min) (Matzuk et 
al.,1990; Murphy et al., 1991; Allegra, 2011). As eLHβ and eCGβ are encode by the same gene 
(Sherman et al., 1992) it is reasonably to hypothesize that eLH has a longer half life compared to the 
other mammalian LH. 
 
1.3.3.2  Bovine FSH b-subunit 
In the bovine species, the FSH b-subunit (bFSHb) is encoded by a gene composed of three 
exons and two introns (ID: 281171). The gene is localized on chromosome 15 and is more or less 4 
kb. 
The gene encode for a sequence of 109 amino acids with six disulphide bridges at Cys1-Cys49, 
Cys15-Cys64, Cys18-Cys102, Cys26-Cys80, Cys30-Cys82, Cys85-Cys92 and two glycosylation sites (N-
glycosidically linked oligosaccharides) at Asn5 and Asn22. The theoretical molecular weight is 
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12972,4 and pI 8,30. As b-subunit is glycosylated theoretical molecular weight and pI are different 
from experimental values. 
In Figure 7 the bFSHb amino acid sequence is compared to the FSHb sequences from 12 
different mammalian species. Table 5 reports the pair-wise comparisons (bovine vs other species) for 
amino acid sequences of these species. 
There is no identical amino acid sequence even between very related animal families 
(ruminants). The sequences of any of these FSHb differ from the other from 5 (pig) to 19 (dog) 
residues. 
 
 
 
Table 5 
Identity percentage between FSH β-subunit 
of 12 different mammalian species in 
comparison to bovine LH β-subunit. 
 
 
Number of different  
Amino acids 
    Identity 
  (%) 
Bufalo 7 93 
Goat 11 90 
Ovine 9 91 
Pig 5 95 
Cat 9 91 
Tiger 11 90 
Dog 19 82 
Mouse 13 88 
Rabbit 12 89 
Rat 15 86 
Human 12 89 
Equine 10 91 
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                  10         20         30         40         50         60         70 
BOVINE    CELTNITITV EKEECGFCIS INTTWCAGYC YTRDLVYRDP ARPNIQKTCT FKELVYETVK VPGCAHHADS 
BUFFALO   ---------- ---------- ---------- ---------- ---------- Y--------- ---------- 
GOAT    RS---------- -----S---- ---------- -------K-- -------A-- ---------- -----R---- 
HEEP     S---------- -----S---- ---------- -------K-- -------A-- ---------- ---------- 
PIG       ---------- -----N---- ---------- -------K-- ---------- ---------- ---------- 
CAT       ---------- -----R---- --A------- -------K-- ----N----- ---------- ------Q--- 
TIGER    K---------- -----R--M- --A------- -------K-- ----N----- ---------- ------Q--- 
DOG       -----V--A- -----R---- V-A------- -------K-A ---S------ -R--A----R -----R---- 
MOUSE    S--------S- -----R---- ---------- -------K-- ----T--V-- ---------R L----R-S—- 
RABBIT  SS--------A- -----R---- ------S--- -------K-- -------I-- ---------R ---------- 
RAT      S--------S- -----R---- ------E--- -------K-- ----T--V-- --------IR L----R-S—- 
HUMAN   NS--------AI -----R---- ---------- -------K-- ---K------ ---------R ---------- 
HORSE   NS--------A- ---------- ---------- -------K-- ---------- ---------- ---------- 
                   80         90        100        109          
BOVINE     LYTYPVATEC HCSKCDSDST DCTVRGLGPS YCSFREIKE 
BUFFALO    ---------- Q-G---G--- ---------- ----S-SR- 
GOAT       ---------- --G---R--- ---------- ----SD-R- 
SHEEP      ---------- --G---R--- ---------- ----SD-R- 
PIG        ---------- --G------- ---------- ----S-M-- 
CAT        ---------- --G------- ----Q----- ----S-M-- 
TIGER      ---------- --G------- ----Q----- ----S-M-- 
DOG        -H-------- --GR------ ---------- ----G-PQQ 
MOUSE      ---------- --G------- ---------- ----S-M-- 
RABBIT     ---------- --GN------ ---------- ----G-M--  
RAT        ---------- --G------- ---------- ----G-M--  
HUMAN      --------Q- --G------- ---------- ----G-M--  
HORSE      --------A- --G--N---- ---------- ----GDM-- 
 
Figure 7 
FSH β-subunit amino acid sequence of 12 mammalian species in comparison to bovine FSH β-
subunit. Cys residues forming the six intrachain disulfides bridges of the β-subunit are highlighetd 
in yellow. 
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1.3.4  Bovine LH and FSH αb heterodimers 
The α and b subunits of the glycoprotein hormones are non-covalently bound to form the 
biological active αb heterodimer. The three different b-subunits may combine with the same common 
α-subunit (Pierce et al., 1971). This data together with the fact that the b-subunit amino acid 
sequence maintain, in all three glycoprotein hormones, the same 12 Cysteine residues (Cys), suggest 
that some regions within the three-dimensional structure of the various b-subunits may be very 
similar among the glycoprotein hormones (Ulloa-Aguirre et al., 2001-A). Therefore the non-similar 
regions are probably those to confer the immunological and biological specificity to the hormone. 
The three-dimensional structure of human CG and FSH (hCG and hFSH) have been determine 
through X-ray crystallography (Fox et al., 2001). In Figure 8 the crystal structure of hFSH is 
represented. The α- and b- subunits have similar folds, consisting on a central cysteine-knot motifs 
from which three b-hairpins extend. The two subunit associate in a head to tail arrangement, forming 
an elongated, slightly curved structure similar to that of hCG. 
 
Figure 8 
Overall fold of hFSH. The b-subunit is shown in red and the α-subunit 
in yellow. The carbohydrate and the disulfide bonds in both subunits 
are represented by ball-and-stick models. The N and C termini of each 
subunit, the N-glycosylated Asn residues and the loops are labeled. 
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No three-dimensional structure of gonadotropins hormones for other mammalian species has 
yet been determined, but alignment of amino acid sequence of both α- and β- subunits (Figure 4, 6, 7) 
show the cysteine residues, forming the intra-chain disulfides bridges, are conserved, suggesting that 
the glycoprotein hormone have similar tridimensional structure in different species. 
The bLH dimer has a theoretical Mr of 23745.89 and a pI of 8.60 while the bFSH as a 
theoretical Mr of 23072.4 and a pI of 7.47. However, since both subunits are glycosylated, 
experimental values significantly differ from theoretical Mr and pI.  
 
1.4  Assays to determine LH and FSH in plasma 
Various assay systems for the estimation of gonadotropin hormones in biological samples have 
been developed through years, and can be classified into two groups. Those that determine some 
response of a biological system to stimulation with LH or FSH (bioassays, both in vivo and in vitro) 
and those that estimate high affinity binding of gonadotropin hormones to molecules which exhibit 
specific properties of molecular recognition (immunoassays and receptor assays) (Rose et al., 2000; 
Kalia et al., 2004). 
Independently from the type of assay, one of the major problems in gonadotropin measure is 
that often there are significant differences between results obtained by different methods. In fact, the 
concentration of gonadotropins measured in the same biological sample can significantly vary 
depending on the assay protocol and on the standard preparation used as reference. The reason is that 
each gonadotropin is intrinsically an heterogeneous mixture of different molecular variants, and 
assays can be selective for particular array of isoforms, as well as standard preparations can have a 
different isoform composition.  
The use of international reference standards with a defined composition to which calibrate the 
FSH and LH assays is of great help in reducing this inter-assay variability. Several highly purified 
reference standards are now available for both human and animal gonadotropins. These standard 
hormone are provided by the National Institute of Diabetes and Digestive and Kidney diseases 
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(NIDDK) or the United States Department of Agriculture (USDA) through the National Hormones 
and Pituitary Program (NHPP, Baltimore, MD). However, despite the use of these international 
standards, discontinuity on quantification of gonadotropins in biological samples by different 
methods still occurs, especially using bioassays. It is thus essential that any measurement of 
gonadotropins include specification both of the standard with which the measured gonadotropins is 
compared and the assay method used for that comparison ( Rose et al., 2000). 
 
1.4.1  Bioassay for gonadotropins  
Gonadotropins were first identified and defined on the basis of in vivo endocrine activity and 
the assays developed for gonadotropins were based on classical endocrine principles. These early 
assays had two main drawbacks. First, there was no assay specific for FSH and LH, and second, 
quantification and hence between-laboratory comparisons were made difficult by a lack of 
standardization. However, with the advancement in biotechnology, various reliable in vitro bioassays 
were developed. Follicle-stimulating hormone bioassays have relied on measurement of aromatase 
activity in primary cultures of immature rat Sertoli cells or rat granulosa cells. Luteinizing hormone 
bioassays have relied on measurement of androgen production in primary cultures of rat interstitial 
testicular cells or mouse Leydig cells.  
While sensitive and accurate, those bioassays are cumbersome and often lacking of analytical 
precision (high intra assay variability). The cloning of the cDNAs of FSH and LH receptors has 
allowed the establishment of cell lines expressing gonadotropin receptors. A permanent cell line is 
used avoiding primary culture of granulosa, Sertoli or Leydig cells, thus significantly improving 
reproducibility and simplifying laboratory procedures. Furthermore, no live animals are used. 
(Christin-Maitre et al., 2000; Christin-Maitre et al., 1996). 
Bioassay based on cloned receptors are now a valuable tool for both diagnostic and research 
applications, but have not so far enabled to routinely measure gonadotropins in plasma, and 
immunoassays (see section 1.4.2) are still used for most of the physiological and clinical studies on 
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serum gonadotropins (Rose et al., 2000; Kalia et al., 2004). The immunoassays offer improvement in 
sensitivity, precision and convenience over bioassays, but cannot provide information about the 
biological activity of the gonadotropin measured (Rose et al., 2000; Kalia et al., 2004). In fact, the 
major advantage of bioassay over immunoassay is the ability to detect changes in the patterns and 
proportions of gonadotropin glycoforms which may be of biological and clinical significance. 
Bioassay for the measurement of the activity of bovine pituitary gonadotropins were previously 
developed both by in vivo and in vitro. The bioactivity of bLH was measured in vivo by the ovarian 
ascorbic acid depletion assay (Reichert, 1962; Courte et al., 1972; Perrera-Marin et al. 2004), 
quantitative hyperemia of Ellis (Reichert, 1962) and ventral prostate test in hypophysectomized rat 
(Courte et al., 1972). In vitro by primary culture of dispersed mouse Leydig cells (Dahal et al., 1993; 
Henricks et al, 1984; Stumpf el al., 1992) and by the MA-l0 cell line, that is a clonal strain of mouse 
Leydig tumor cells that has receptors for LH and respond to LH stimulation by progesterone 
secretion (Dahal et al., 1993; Baenzinger et al. 1992).  
The bioactivity of bFSH has been previously tested in vivo by the ovarian weight augmentation 
assay of Steelman and Pohely (Reichert, 1971), in vitro by a method based on the estradiol produced 
from dispersed Sertoli cells (Grimeck et al., 1979; Wu et al., 1993). The rat granulosa cell line 
FSHR-17 has been recently shown to be a reliable in vitro model for studying the FSH activity in the 
bovine species (Borromeo et al., 2004). This cell line was established by immortalisation of 
preovulatory rat granulosa cells by co-transfection of primary cells with SV40 DNA, Ha-ras gen and 
rat FSH receptor (r-FSHR) plasmid (Keren-Tal et al., 1993). The cells express approximately 27,000 
r-FSHR per cell with a Kd of 115 pM, and respond specifically to FSH by dose-dependent secretion 
of progesterone. The sensitivity of the FSHR-17 bioassay is one order of magnitude lower than in the 
classical primary Sertoli cell bioassay (Ritzen et al., 1982), but much better than in other bioassays 
based on cloned receptors (Christin-Maitre et al, 2000). 
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1.4.2  Immunoassay for gonadotropins  
Since the development of the first radioimmunoassay (RIA) for insulin (Yalow et al., 1959), the 
use of antibodies in endocrinological research has become widespread, and now various 
immunological assay methods have been developed for the measurement of gonadotropins in human 
as well in domestic animals (Niswender et al., 1969; Adam et al., 1975; Matteri et al., 1987; Crowe 
et al., 1997; Ginther et al., 1999; Valares et al., 2007; etc). Immunochemical systems improved 
considerably the sensitivity and lowered inter-assay variation compared to bioassays, especially with 
the introduction of hybridoma techniques, which allowed the production of specific mAbs to the 
given hormone. In fact, the immunoassays using polyclonal antisera, often lack specificity and 
sufficient sensitivity to measure the relative low gonadotropin concentration in biological fluids (Zou 
et al., 1991). Furthermore, conventional polyclonal antisera is hampered by α-chain identity within a 
given species, by β-chain similarities, by cross-contamination of immunogens and/or standards with 
other hormones, as well as by batch to batch variations of polyclonal antisera. Monoclonal antibodies 
have the potential to overcome these problems (Hojo et al., 1985).  
Serum gonadotropins levels are often determined by radioimmunoassay (RIA), both in humans 
and animals (see section 1.4.2.1). However, even though RIA is a reliable and accurate method, the 
procedure uses radioisotopes 125I as label, suffering of various disadvantages. In fact, there are safety 
consideration to take in account when using isotopic label, such as health hazards, restrictive 
regulations for radioactive waste disposal, more over there is immunological instability of the labeled 
substance, limited shelf-life of iodine tracers, limited licensing and expensive equipment (Valares et 
al., 2007; Peclaris et al., 2003; Zou et al., 1991). Such constraints have necessitated the development 
of non-isotopic methods, such as enzyme immunoassay (EIA) (see section 1.4.2.1).  
The selectivity of immunoassays is dependent upon the epitope specificity of the antibodies 
used in the systems. For the glycoprotein hormones, epitope specificity is dependent largely upon 
amino acid sequences and only to a minor extent on oligosaccharide structures (Jeffcoate, 1993). The 
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consequence is that immunoassays are largely blind to changes in the patterns and proportions of 
gonadotropin glycoforms. 
There is considerable experimental evidence that glycosylation plays little part in the 
immunological properties of glycoprotein hormones. Luteinizing hormone, for example, has to be 
extensively deglycosylated before there is any effect on antigenic structure (Sairam et al., 1988). The 
hormone erythropoietin (which is 40% glycosylated) can be completely deglycosylated without 
affecting its immunogenicity, (Jeffocate, 1993). For hCG also immunogenicity and epitope mapping 
are not affected by deglycosylation (Schwarz et al., 1991).  
It is possible that glycosylation could have subtle effects on conformation and thus antigenicity. 
Deglycosylation of TSH has been shown to have no effect on b-chain epitopes but certain α-chain 
epitopes were altered (Papandreou et al., 1990). It should be recognized that complete removal of 
oligosaccharides is far from subtle and not representative of the physiological variants that occur.  
The overall conclusion remains that glycosylation is immunologically unimportant. Incidentally 
it is worth pointing out that any subtle changes affecting antibody binding affinity are more likely to 
be revealed in traditional competitive RIAs than in the reagent excess two-site immunometric 
methods. 
 
1.4.2.1  Immunoassay for bovine FSH and LH 
Numerous immunoassays to quantify bLH and bFSH in the peripheral circulation have been 
described in literature. In Tables 6 and 7 are reported a schematic review of the RIAs and EIAs 
developed for the measurement of these two gonadotropins in the bovine specie. Tables highlight the 
technique, the standard and the antibody used by each author. 
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Table 6 
Schematic review of the RIAs (A) and EIAs (B) developed for the measurement of LH in the bovine 
plasma. Tables highlight the technique, the standard and the antibody used by each author. 
(A) RADIO-IMMUNO-ASSAYS FOR BOVINE LH 
 REFERENCE METHOD 
Niswender et al., 1969 - Std and labeled hormone: bLH (LER-791-1) 
- In house antiserum anti-bLH and anti-rabbit gamma globulin 
Golter et al; 1973 - Std: bLH (NIH-LH-B7) 
- First antibody: rabbit anti-bLH serum 
- Second antibody: goat anti-rabbit gamma globulin 
- Sensitivity 0.1 ng/ml 
Adam et al., 1975 - Std: NIH-LH-S16 
- Labelled hormone: ovine LH (LER-1056-C2) 
- Sensitivity 0.25 ng/ml 
Zaied et al., 1980 - Modified from Niswender et al., 1969.  
- Standard: NIH-LH-B-8 
- Label 125I used instead of 131I 
Rawlings et al., 1984 - Modified from Niswender et al., 1969. 
- Labelled hormone: ovine LH (LER 1017-2) 
- First antibody in house produced 
- Sensitivity: 50 pg/ml 
Hamernik et al., 1987 - Modified from  Niswender et al., 1969. 
- Standard: NIH-LH-S-21 
- Sensibility: 0.15 ng/tube 
Schillo et al., 1988 - Modified from Niswender et al., 1969. 
- Std and labeled hormone: NIADDK-oLH-25 
- Ovine LH antiserum (GDN-15)  
- Sensitivity 0.025 ng/tube 
Wolfe et al., 1989 - Modified from Adams et al., 1975. 
- Standard: NIH-LH-B-7 
- Labelled hormone: ovine LH (LER-1056-C2) 
- Rabbit antisera anti-oLH (TEA-RAOLH #35) 
- Sensitivity: 88 pg/ml 
Chenault et al., 1990 - Modified from Niswender et al; 1969. 
- Standard: NIH-oLH-S24 
Evans et al., 1992 - Modified from Rawlings et al., 1984. 
- Standard: NIDDK-bLH-4 
- Sensitivity 0.1 ng/ml 
Wolfe et al., 1992 - Modified from Adams et al., 1975 and Wolfe et al., 1989.  
- Standard: NIH-LH-B7 
- Labelled hormone: highly purified iodinated ovine LH (LER-1056-C2) 
- Antiserum anti-oLH in rabbits (JJRRaOLH #%I) 
- Sensitivity: 50 pg/ml 
Imwalle  et al., 1998 - Modified from Hall et al., 1994.  
- Labelled hormone: highly purified LH (LER-1374A), supplied by Dr. L.E. Reichart 
- Ovine LH antiseru AFP-192279, supplied by NHPAgency (Bethesda, MD) 
- Sensitivity: 0.05 ng/tube 
Ginther et al., 1999 - Standard and labeled serum: USDA-bLH-B-6 
- USDA-309-684 as the primary antiserum 
- Sensitivity 0.07 ng/ml 
Honaramooz et al., 
2000 
- Modified from Rawlings et al., 1984 and Evans et al., 1992. 
- Standard: NIDDK-bLH4  
- Sensitivity 0.1 ng/ml 
Hampton et al., 2003 - Modified from Zaied et al., 1980 
- Ovine LH antiserum TEA # 35 (J. J. Reeves, Washington State Univ., Pullman, 
WA). 
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Valares et al., 2007 - Fist antibody: Mab 0220-518b7 anti-bLH β-subunit (518b7 antiLH) supplied by Dr Jan 
Roser 
- Labelled antibody: anti-ovine-LH (NIDDK, oLH-26; AFP 5551B)  
- Standards: oLH (NIDDK-oLH-I-4) 
Atkins J.A., et al; 2008 - Modified from Hampton et al., 2003. 
- Primary antibody: antibovine LH monoclonal antibody (518B7; Matteri et al., 1987) 
- Sensitivity 0.06 ng/ml 
Perry et al., 2008 - LH antisera (NHPP)  
- Sensitivity 0.125 ng/m 
Palhao et al., 2009 - Modified from  Bolt & Rollins., 1983, and Ginther et al., 1999.  
- Standard and labelled hormone: USDA-bLH-B-6 
- Primary antiserum: USDA-309-684P  
- Sensitivity: 0.1 ng/ml 
Ginther et al., 2010 - Modified from Palhao et al., 2009 and Hannan et al., 2010. 
- Sensitivity: 0.06 ng/ml  
Hannan et al., 2010 - RIA method as Palaho et al., 2009 
- Primary antibody: AFP192279 from National Hormones and Pituitary Program  
- Sensitivity: 0.12 ng/ml 
Wankowska et al., 2010 - Double-antibody RIA for bLH 
- Standard: NIH-LH-B6 
- Antisera: anti-rabbit-gammaglobulin 
- Sensitivity: 0.312 ng/ml 
Giordan et al., 2012 - Modified from  Palhao et al., 2009 and Hannan et al., 2010. 
- Sensitivity: 0.12 ng/ml 
 
(B) IMMUNOENZIMATIC ASSAYS FOR BOVINE LH 
REFERENCE METHOD 
Spearow et al., 1987 - different systems: 
- a) Three different standard: USDA-bLH-B5, bLH-LER-1072-7 supplied by 
Dr. Leo Reichert, oLH b-subunit supplied by Dr. Darrel Ward  
- Anti-oLH number 15 serum obtained from Dr. Gordon Niswender and Dr. 
Terry Nett.  
- Mouse monoclonal antibody clone 0220-518B7 anti-bLH b-subunit (518B7 
anti-LH) obtained from Dr. Jan Roser 
- Chicken anti-oLH b-subunit Dl 1-61 (chicken anti-LH) produced by 
immunizing hens with oLH b-subunit. 
Prakash et al., 2002 - Standard: Bovine LH (USDA-bLH-B-6).  
- Labeled Biotinylated Bovine LH (USDA-bLH-B-6).  
- Rabbit polyclonal anti-bovine LH antiserum (USDA- 309-684P)  
- First coating with goat IgG anti-rabbit IgG 
- Sensitivity 0.31 ng/ml 
Schneider et al., 2002 - Standard bLH was provided from Biotrend (Cologne, Germany)  
- Polyclonal rabbit anti-bLH mAb  
- Labelled Mab 518 B7 against bLH 
- Sensitivity 0.03 ng/ml 
Faure et al., 2005 - Standard: oLH CY1083 
- Monoclonal antibody to bovine LH b-subunit 518B7  
- Biotinylated monoclonal antibody to human a-subunit  
- Sensitivity: 0,1 ng/ml 
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Table 7. 
Schematic review of the RIAs (A) and EIAs (B) developed for the measurement of FSH in bovine 
plasma. Tables highlight the technique, the standard and the antibody used by each author. 
(A) RADIO-IMMUNO-ASSAYS (RIA) FOR BOVINE FSH 
  REFERENCES METHOD 
Bolt and Rollins., 1983 - Std and labeled hormone: USDA-FSH-BP-1 
- Antiserum: USDA-5-0122 
Hamernik et al., 1987 - NIADDK-oFSH radioimmunoassay kit 
Garverick et al., 1988 - Standard: USDA-bFSH-B-1 
- Labelled hormone: NIAMMD-oFSH-I-1 
- Antiserum anti-ovine FSH: NIAMMD-anti-oFSH-1 
- Sheep anti-rabbit gamma globulin  
Henderson et al., 1989 - FSH antiserum: NIAMDD-anti-oFSH-I (AFP-C5288113) 
- Standard: NIAMDD-oFSH-RP-1 
- Labelled hormone: NIAMDD-oFSH-I-1 (AFP-5679C) 
- Sensitivity: 0.05-0.1 ng/tube 
Chenault et al., 1990 - NIADDK-oFSH radioimmunoassay kit 
Adams et al., 1992 - Modified from Bolt and Rollins 1983. 
- Standard: USDA-bFSH-B-1 
- Labelled hormone: USDA-FSH-BP-3 
- Antiserum anti-bovine FSH: USDA 5-pool 
- Sensitivity: 5 ng/ml 
Cupp et al., 1995 - Standard and labelled hormone: oFSH (LER-1976-A2) 
- Rabbit antisera o-FSH (JAD-RAoLH n. 17-6 7,9) 
- Sensitivity 45 pg/ml 
Gong et al.,1995 - Anti ovine FSH serum:NIDDK-anti-oFSH-1 
- Standard: USDA-bFSH-I-2 
- Labelled hormone: NIDDK-oFS-I-1 
- Sensitivity: 0.11 ng/ml 
Crowe et al., 1997 - anti-FSH antibodies: NIDDK anti-ovine FSH, JAD anti-ovine FSH, USDA anti-
bovine FSH 
- Standard: USDA bFSH-B-1/I-2 
- Labelled hormones: USDA-oFSH-I-2, LER 1976a ovine FSH, USDA bFSH-I-2 
Hampton et al., 2003 - Modified from Garverick et al., 1988. 
- Standard: NIAMMD-oFSH-RP-1 
Lane et al., 2008 - Modified from Crowe, et al., 1997. 
- Standard: USDA-bFSH-I-2 
- Labelled hormone: ovine FSH AFP-4117A 
- Antisera: NIDDK anti-ovine FSH (AFP-C5288113) 
- Sensitivity: 0,01 ng/ml  
Palhao et al., 2009 - Modified from Bolt & Rollins 1983, and Adams et al. 1992. 
- Standard and labelled hormone: USDA-bFSH-I-2 
- Primary antiserum: NIDDK-anti-oFSH-1  
- Sensitivity: 0.02 ng/ml 
 
(B) IMMUNOENZIMATIC ASSAYS (EIA) FOR BOVINE FSH 
REFERENCE METHOD 
Prakash et al., 1999 - Standard: USDA-bFSH-1-2 
- Antisera: sheep IgG and anti-bovine FSH beta (USDA-5 pool) 
- Sensitivity: 0,125ng/ml 
Zou et al.,1991 - Standard: purified bFSH from Institute of Zoology (Chinese Acad Sci) 
- In house produced mAbs 
- Sensitivity: 1 ng/ml 
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Despite the relatively high number of publications reporting the measure of bFSH and bLH, the 
two gonadotropins in bovine plasma are currently measured only in a limited number of specialized 
laboratories. The first reason is that no reliable kits can be purchased on the market, and therefore all 
immunoassay have to be developed in house. Second, that antibodies as well as hormone standards to 
set up such immunoassays are almost exclusively provided in small and defined quantity by the 
USDA. Third, that bFSH and bLH are species-specific (both amino acid and oligosaccharides differs 
among species), limiting the accurate hormone detection to homologous assays. 
As reported above, a major problem with the development of LH and FSH immunoassays in 
the bovine species is the limited availability of pure bLH and bFSH to be used as immunogen and/or 
reference standard. The only source of bLH and bFSH is in fact the pituitary gland, since no 
recombinant protein is available. Biologically active bLH has been obtained from CHO cells (Kaetzel 
et al., 1985; Kaetzel et al., 1988), and biologically active bFSH from plant and insects (Van De Wiel 
et al., 1998; Dirnberger et al., 2001), but the process did not reach the efficiency required for large-
scale production. The use of recombinant human gonadotropins is hampered by the fact that anti-bLH 
and anti-bFSH antibodies bind with very low affinity to human gonadotropins (Kofler et al., 1981; 
Matteri et al., 1987). Furthermore, because LH, TSH and FSH have similar structures and 
overlapping charge, their separation by methods based on acid-base separation is problematic and 
often the LH and FSH preparations recovered are contaminated with other hormones. 
Finally, despite the many advantages of mAbs over polyclonal antibodies, very few mAbs have 
been produced to animal LH and FSH. To the best of our knowledge, only two reports have been 
published on the production and characterization of anti-bLH mAbs (Kofler et al., 1981; Matteri et 
al., 1987), and only one of these mAbs (i.e: mAb 518B7, Matteri et al., 1987) resulted suitable for 
application in ELISA (Matteri et al., 1987; Spearow et al., 1987; Schneider et al., 2002). As well, 
while mAbs against hFSH are widely available, mAbs generated against bFSH are much less 
common (Miller et al., 1987; Zou et al., 1991), and they have never been used for developing an 
immunoassay.   
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2.  AIM OF THE STUDY 
 
In cattle plasma bLH and bFSH are currently measured only in a limited number of 
laboratories, using non-commercial immunoassays, developed using antibodies and/or reference 
hormones provided from external research institutions. Furthermore despite the well-known 
advantages of mAbs over polyclonal antibodies and their significant contribution to the development 
of modern research in endocrinology in both human and veterinary medicine, very few mAbs have 
been produced to bovine LH and FSH.  
The aim of the present study was therefore to develop and validate two novel species-specific 
mAb-based ELISAs for measuring bLH or bFSH in bovine plasma, based on reagents (antibody and 
reference standard) produced in our laboratory, thus to ensure long-term continuity in large-scale 
operation with this ELISAs. Specifically, the objectives were: (1) to produce a panel of anti-bLH and 
anti-bFSH mAbs by immunizing with standard hormones obtained from the USDA; (2) to select 
mAbs suitable for immuno-affinity chromatography purification of bLH and bFSH from pituitary 
glands; (3) to combine the mAbs and the purified gonadotropins to develop two ELISAs for bLH and 
bFSH detection. 
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3. MATERIALS AND METHODS 
 
3.1  MAbs production and characterization 
BALB/c mice were immunized with bFSH obtained from Fitzgerald Industries International 
(Concord, MA, USA) or with bLH from USDA (USDA-bLH-B-6, kindly provided by Dr. A.F. 
Parlow through the USDA Animal Hormone Program, Germoplasm and Gamete Physiology 
Laboratory, Beltsville Agricultural Research Center, Beltsville. MD, USDA). Reference standard of 
USDA-bTSH-I-1 and USDA-bFSH-I-2 were also kindly provided by Dr. A.F. Parlow. 
The protocol was approved by the Animal Experimentation Ethic Committee of the State 
University of Milan and consisted in immunizing BALB/c mice, weighing 10-12 g. by two 
intramuscular injections of 50 and 25 mg of bLH or bFSH in 150 mL saline solution containing 12 mg 
AbISCO-100 adjuvant (ISCONOVA AB, Uppsala, Sweden) with a three-week interval. They then 
received a booster intramuscular injection of 25 mg of bLH or bFSH in saline-AbISCO-adjuvant four 
days before fusion.  
Splenic lymphocytes were fused with P3X63Ag8U.11 myeloma cells using poly(ethylene 
glycol) 1450 (PEG solution 50%, Hybri Max, SIGMA) according to a standard procedure (Secchi et 
al., 1991). 
The so produced hybridomas were screened for their ability to bind respectively bLH and bFSH 
in enzyme immunoassay. For screening we used a direct ELISA, where ninety-six-well microtiter 
plates were coated with bLH or bFSH (0.1 µg/well) in Na2CO3–NaHCO3 buffer 50 mM, pH 9.6, 50 
ul/well; overnight at 4 °C. The plates were then washed with PBS-T, and saturated with 100 ul/well 
of BSA, 1% in PBS-T (1 h at 37 °C). After washing with PBS-T, hybridoma culture medium was 
added (50 ul/well) and the plates were incubated at 37 °C for 3 h. They were then washed again with 
PBS-T and incubated with 50 ul/well of rabbit anti-mouse immunoglobulins-alkaline phosphatase 
conjugated (Sigma-Aldrich, Milan, Italy), 1/2000 in PBS-T containing BSA 0.1%; 1.5 h at 37 °C. 
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The wells were washed with PBS-T and the enzymatic reaction was carried out by adding 50 ul/well 
of freshly prepared p-nitrophenyl phosphate (pNPP) 1 mg/ml in 10 mM diethanolamine (pH 9.8) 
containing 0.5 mM MgCl2. The reaction was let proceed for 1 h at 37°C and then the absorbance was 
measured at 405 nm using an automated microtiter plate reader (SpectraCount, Canberra Packard, 
Milano, Italy).  
Hybridomas found to be positive against bLH were also screened for binding to bFSH (USDA-
bFSH-I-2) and bTSH (USDA-bTSH-I-1), while hybridomas positive against bFSH were also 
screened against bLH (USDA-bLH-B-6) and bTSH (USDA-bTSH-I-1). For screening a direct 
ELISA was again performed. 96-well plates were coated with the hormone (0.1 mg/well) and, after 
incubation and washing, hybridoma culture medium was added. The binding of mAbs to the 
adsorbed hormone was revealed with AP-conjugated rabbit anti-mouse immunoglobulins (Sigma-
Aldrich, Milan, Italy) as described above.  
The antibody class of mAbs was determined by enzyme immunoassay using the mouse-
hybridoma subtyping kit (Life Technology, Italy).  
Positive clones, producing antibodies belonging to the IgG class, were subcloned by limiting 
dilution and expanded in culture to obtain antibodies. The so obtained monoclonal antibodies were 
precipitated from the culture supernatants with 50% ammonium sulphate solution, dialyzed against 
10 mM phosphate buffer, 0.148 M NaCl, pH 7.2 (PBS) and purified by affinity chromatography on 
HiTrap r-Protein A columns (GE Healthcare Life Science, Italy). The dissociation constant (Kd) of 
each mAb to his antigen was determined by the immunoenzymatic method described by Schots 
(Schots et al., 1988). 
According to their characteristics four mAbs: two anti-bLH β-subunit (N6H7 and N3G8), one 
anti-bFSH β-subunit (A3C12) and one anti-α subunit (D2H1) were selected for further studies. 
Samples of each (0.5 mg) were conjugated with HRP using the periodate method (Tijssen., 1985). 
MAbs N3G8 (0.5 mg) and D2H1 (0.5 mg) were conjugated with biotin (Secchi et al., 1988), 
fractionated and stored at -80°C. 
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3.1  Epitope mapping  
Bovine LH and bFSH antigenic epitope mapping was performed by a labeled antibody 
competition test (LACT) (Aston et al., 1985). Serial dilutions of unlabeled mAb were added to bLH 
or bFSH-coated plates (0.05 µg/well) to displace the mAb-HRP from the immobilized hormone. The 
labeled mAb was used at a dilution giving absorbance of about 1.0 in the absence of the competing 
mAb (B0) under the conditions used for the assay. The percentage of competition was established on 
the basis of the EC50 calculated from each curve (Borromeo et al., 2003). We took the EC50 obtained 
using the same mAb as competing and labeled mAb as 100%. 
 
3.3  Immunoaffinity purification 
HiTrap NHS-activated HP columns (1 mL; GE Healthcare Life Science, Italy) were used. 
According to the manufacturer's directions we coupled 10 mg of the protein A purified mAb-N6H7 
and A3C12 for bLH and bFSH purification respectively. Monoclonal antibodies were chosen 
according to their characteristics. The derivatized columns were stored in PBS. 
Bovine pituitary glands were collected just after slaughter in a local abattoir and immediately 
frozen, then stored at -20°C until required. The pituitaries were not selected for age, sex, reproductive 
status or breed of the donor. Crude bFSH and bLH extracts were obtained from bovine pituitaries 
following the first steps of the procedure described by Reichert (Reichert et al., 1975). Briefly, 100 g 
of pituitaries were homogenized in distilled water at 4°C and extracted for 8h at pH 5.5. After 
centrifugation (4500 x g, 1h) supernatant and precipitate were separated. The supernatant containing 
bFSH was precipitated with 1.8 M ammonium sulphate and the so obtained supernatant was 
precipitated a second time with 3 M ammonium sulphate. The first precipitate, containing bLH, was 
extracted at pH 4.0 with 0.1 M ammonium sulphate for 3h. The supernatant from centrifugation was 
recovered and precipitated the first time with 3 M ammonium sulphate at pH 4.0 and the second time 
with 3.5 M ammonium sulphate at pH 4.0. The bFSH and bLH precipitates were recovered and 
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dialyzed against several changes of distilled water for 24h. The precipitates were removed by 
centrifugation (10000 x g, 30 min), while the supernatants (bLH-1 or bFSH-1) were adjusted to 10 
mM phosphate, 0.148 M NaCl, pH 7.2.  
The crude hormone fractions, bLH-1 and bFSH-1, were then loaded onto the N6H7-affinity 
column and A3C12-affinity column respectively, at a flow-rate of 1 mL/min. The columns were then 
washed with 5-10 column volumes of PBS and the bound bLH or bFSH were eluted with citrate 
buffer 0.1 M, pH 3.0. The fractions containing the eluted bLH (N6H7-bLH) and bFSH (A3C12-
bFSH) were immediately neutralized with TRIS 1M and concentrated to 0.5 ml in PBS 10 M, pH 7.2 
using Amicon Ultra-4 concentrators (10000 MWCO, Millipore Corporation, MA, USA). The 
columns were re-equilibrated with PBS between batches. 
Purified bLH and bFSH were fractionated and stored at -80°C. The protein content of each 
fraction was determined by the method of Lowry (Lowry et al., 1951). 
 
3.4  Protein characterization 
3.4.1  Biological activity 
bLH-biological activity: The N6H7-bLH biological activity was determined in vitro on MA-10 
cells (a kind gift from Dr. Mario Ascoli, University of Iowa, Iowa City, IA), a mouse Leydig tumor 
cell line responding specifically to LH by dose-dependent secretion of progesterone. 
Cells were maintained with standard techniques (Ascoli, 1981; Swinnen et al., 1991) in RPMI 
medium with penicillin (100 U/ml), streptomycin (100 µg/ml) and 15% horse serum (HS). For 
bioassay, cells were cultured in 0.5 ml medium containing 15% HS for 48 h on NUNC 24-well plates 
(0.5 x 105 cells/well). After this, medium was removed and the cells were washed with DPBS. After 
medium removal and DPBS washing bovine LH at various concentrations (0.5-250 ng/ml) was added 
in RPMI medium without serum and cells maintained in CO2 incubator for 4h.  
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Progesterone accumulated in the culture medium was determined by a competitive enzyme 
immunoassay, using an in-house produced anti-P4 monoclonal antibody as capture antibody and 
progesterone-11-HS-HRP (Fitzgerald Industries International, Concord, MA, USA) as labeled 
hormone. The cross-reactivity of the antibody was 5% for testosterone and 0% for 17β-estradiol. 
Assay sensitivity was 0.5 ng/ml. The range of the standard curve was from 250 to 0.5 ng/ml, and 
intra- and interassay coefficients of variation were 9.2 % and 12.4%. 
Bioactive bLH was measured in triplicate and the experiment was replicated five times. The 
relative potency was interpolated from the standard curve plotted using the standard reference 
preparation USDA-bLH-B6. 
Before statistical analysis, the dose-response curves were log-dose-transformed. Parallelism of 
the response curves generated by the various bLH preparations was determined by comparing the 
slopes and the y intercept of the regression lines fitting the data points within the linear range of the 
curves (ie, 1-2.5 ng/ml) with a statistical method included in the GraphPad Prism software (GraphPad 
Software, San Diego, CA, USA). The method tests the null hypothesis that the slopes are all 
identical: if the P value (two-tailed) is greater than 0.05, it concludes that the lines are parallel. If 
slopes are indistinguishable the software calculate a second P value testing the null hypothesis that 
the y intercepts are equal. If also this second P value (two-tailed) is greater than 0.05, it concludes 
that the lines are identical.  The ED50 of the curves was defined as the amount of bLH required to 
give 50% of the maximum response, under the conditions established for the assay with maximum 
response defined as the top of the dose-response sigmoid curve plotted with increasing concentrations 
of each treatment (all preparations gave rise to the same maximal stimulation) and was calculated 
using a 4-parameter log dose-response sigmoid curve fitting the whole range of bLH doses tested 
(0.5-250 ng/mL). 
bFSH-biological activity: The A3C12-bFSH biological activitiy was determined in vitro on 
FSHR-17 cells (Keren-Tal et al., 1993), a preovulatory rat granulosa cell line immortalized by co-
transfection of primary cells with SV40 DNA, Ha-ras gen and rat FSH receptor (r-FSHR) plasmid. 
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The cells express approximately 27,000 r-FSHR per cell with a Kd of 115 pM, and respond 
specifically to FSH by dose-dependent secretion of progesterone.  
Cells were maintained on Petri dishes (100mm) (NUNC, Roskilde, Denmark) containing 8ml 
DMEM/ F12 medium (1:1) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml) and 
5% fetal calf serum (FCS). For bioassays, cells were cultured in 0.5 ml medium containing 5% FCS 
for 24 h on NUNC 24-well plates (0.5 x 105 cells/well) before hormone stimulation, which was done 
without changing the medium. Bioactive bFSH was measured in triplicate at four or five dose levels 
(from 140.0 to 8.7 ng/ml for A3C12-bFSH) and the experiment was replicated three times. The 
relative potencies were interpolated from the standard curve plotted using the standard reference 
preparations USDA-bFSH-I-2 and USDA-bFSH-B-1. 
Progesterone accumulated in the culture medium after 24 h incubation with the appropriate 
treatment was determined by competitive enzyme immunoassay as described above for bLH 
bioassay. Statistical analysis was carried out as described for bLH bioassay. 
 
3.4.2  SDS-PAGE and Western blot 
SDS-PAGE was done both under reducing and non-reducing conditions in polyacrylamide 
gradient gel (7%-20%) overlaid with 5% stacking gel. We used a Minigel apparatus (Biometra, 
Göttingen, Germany) and applied a constant current of 10 mA for 15 min and successively a constant 
voltage (200 V) for about 1 h (Berrini et al., 1991).  
Gels were loaded with 1 µg of N6H7-bLH, 1 µg of USDA-bLH-B-6, 1 µg of A3C12-bFSH and 1 µg 
of USDA-bFSH- I-2 and stained with silver nitrate.  
All samples, separated in SDS-electrophoresis in reducing and non-reducing conditions were 
transferred by Western blotting to nitrocellulose sheets. Blotting was performed at 350 mA for 2.30 h 
in transfer buffer (25 mM Tris, 192 mM Gly, 20% MetOH). After blotting nitrocellulose sheet was 
first washed in PBS-T and saturated with BSA 1% in PBS-T for 1 h. After washing the nitrocellulose 
sheet was immunodetected overnight with mAbs (mAb-D2H1 and N6H7, 10 µg/ml; mAbs N3G8 and 
37 
 
A3C12, 2 µg/ml). Nitrocellulose sheet was washed in PBS-T and HRP-labeled anti-mouse 
immunoglobulins was added for 3 h. After more PBS-T washing, a chemiluminescent substrate 
(LiteAbot PLUS, Euroclone, Pero (MI), Italy) was added and the chemiluminescence signal was 
measured with Bio-Rad Chemi-Doc (Bio-Rad, Italy). 
 
3.4.3  Isoelectric focusing 
IEF was carried out in 5% polyacrylamide pre-cast gels (Servalyt precotes, pH 3–10, 125 
x125mm, 300 mm; SERVA, Heidelberg, Germany) at 7°C using Multiphor equipment (GE 
Healthcare Life Science, Italy). After pre-focusing (20 min at 6 mA), N6H7-bLH, A3C12-bFSH (10 
µg both) and isoelectric point standards (SERVA Liquid Mix IEF Markers 3–10, SERVA, 
Heidelberg, Germany) were loaded, and the electrophoresis proceeded for another 3.5 h at 6 mA 
(2000 V). Gels were stained with silver nitrate. 
 
3.4.4  NanoLC-ESI-MS/MS and protein sequencing 
N6H7-bLH: Affinity purified bLH was identified using nanoLC-ESI-MS/MS (Proteome 
Factory AG, Berlin, Germany). The MS system consisted of an Agilent 1100 nanoLC system 
(Agilent, Waldbronn, Germany), PicoTip electrospray emitter (New Objective, Woburn, MA) and an 
Orbitrap XL mass spectrometer (ThermoFisher, Bremen, Germany), PicoTip electrospray emitter 
(New Objective, Woburn, MA) and an Orbitrap XL mass spectrometer (ThermoFisher, Bremen, 
Germany).  
Protein bands obtained after SDS-PAGE under reducing conditions were trypsin-digested in-
gel (Promega, Mannheim, Germany) and applied to nanoLC-ESI-MS/MS. Reduction of the 
disulphide bonds was deemed essential, as digestion of the nonreduced subunits results in large 
tryptic cores which are of little analytical significance. We also proceeded with treatment with DTT 
and iodoacetamide before the gel run, to alkylate cysteines and prevent incorrect disulphide pairs 
from reforming, which would have complicated trypsin digestion and mass assignments. Peptides 
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were trapped and desalted on the enrichment column (Zorbax SB C18, 0.3 x 5 mm, Agilent) for 5 
min using 2.5% acetonitrile and/or 0.5% formic acid as eluant, then separated on a Zorbax 300 SB 
C18, 75 mm x 150 mm column (Agilent) using an acetonitrile and/or 0.1% formic acid gradient from 
5% to 35% acetonitrile within 40 min. MS/MS spectra were recorded data-dependently by the mass 
spectrometer according to the manufacturer’s recommendations. Proteins were identified using the 
Mascot search engine MS/MS ion search (Matrix Science, London, England) and nr protein database 
(National Center for Biotechnology Information, Bethesda). Ion charges in search parameters for ions 
from ESI-MS/MS data acquisition were set to “1+, 2+, or 3+” according to the instrument’s and 
method’s common charge state distribution. 
A3C12-bFSH: Affinity purified bFSH was identified by N-terminal sequence analysis after 
SDS-PAGE and blotting onto PVDF membranes, following the method described by Dunbar 
(Dunbar et al., 1994). The analyisis was kindly done by Dr. B. Dunbar (University of Aberdeen, 
Scotland). 
 
3.4.5  Amino acid analysis 
N6H7-bLH and A3C12-bFSH (2 ug) were hydrolyzed in 6 M HCl under vacuum at 105°C for 
24h. The amino acid analyses were done by reversed-phase LC with pre-column derivatization with 
AccQ-fluor reagent, as indicated by manufactures (Waters AccQ-tag Chemistry Package, Instruction 
Manual Waters Corp) (Water Corporation, Milford, MA). 
 
3.5  Development and validation of the ELISA for bLH 
Polystyrene microtiter plates (96 wells, flat bottom; Maxisorp, Nunc) were used. For the first 
coating we added 1 µg of mAb-N6H7 dissolved in 100 µL of Na2CO3/NaHCO3 buffer 50 mM, pH 
9.6. The plates were incubated overnight at 4°C. After washing three times with 10 mM phosphate 
buffer, 0.3 M NaCl, 0.1% Tween 20 pH 7.2 (PBS-T), the plates were saturated for 1h at 37°C with 
300 µL of BSA 1% in PBS-T. After washing with PBS-T, bLH (N6H7-bLH) and samples were 
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added (100 µL/well). Standard and samples were diluted in PBS-T containing 0.1% BSA. The plates 
were incubated overnight at 4°C. The next day plates were decanted and washed five times with 
PBS-T before addition of 100 µL of biotinylated mAb-N3G8 diluted 1/10000 in PBS-T, BSA 0.1%. 
The plates were incubated for 2h at 37°C with constant agitation. After five washes the wells were 
filled with 100 µL of avidin-peroxidase (0.1 µg/mL in PBS-T, BSA 0.1%) and further incubated for 
2h at 37°C. The plates were washed five times and the enzyme substrate solution (3 mM o-
phenylenediamine in 0.1M phosphate citrate buffer pH 5.0, 0.01% H2O2) was added (100 µL/well). 
The plates were incubated in the dark for 15 min at room temperature and the reaction stopped with 1 
M H2SO4 (100 µL/well). Absorbance was measured at 490 nm with a microtiter plate reader. 
  
3.5.1  Analytical specificity 
The slope of the curve with N6H7-bLH was compared with the slope of the curves obtained 
using serial dilutions of USDA-bLH-B6, bovine plasma and bovine pituitary extract. The pituitary 
extract was prepared as previously described (Secchi C., 1988), and assayed starting at the protein 
concentration of 0.8 mg/ml. The experiment was repeated 3 times and parallelism was assessed 
within each experiment using GraphPad PRISM 5.0 software package, as described in the bLH 
biological activity (see section 3.3.1). The percentage of cross-reactivity was calculated on the basis 
of the ED50 calculated from each curve. 
 
3.5.2  Cross-reactivity 
Serial dilutions of bFSH (USDA-bFSH-I-2), bTSH (USDA-bTSH-I-1), ovine-LH (USDA-
oLH-I-2, kindly provided by dr. Parlow), human chorionic gonadotropin (hCG, Vetecor 2000 U.I.) 
and pig, horse, dog, and rabbit pituitary extracts, prepared as described previously for bovine extract, 
were tested in the ELISA starting at a protein concentration of 8 mg/ml. The hormones were diluted 
in PBS-T, BSA (0.1%). Cross-reactivity coefficients (%) were calculated as the bLH concentration 
divided by the cross-reactant concentration providing the same signal in ELISA.  
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3.5.3  Accuracy and reproducibility 
Graded doses of bLH standard were added to a bovine plasma with known bLH content. The 
samples were tested by ELISA and the correlation between the measured and the added 
concentrations was established. Intra- and interassay coefficient of variation was calculated analyzing 
5 bovine plasma samples. Plasmas were assayed several times either in the same or in different 
plates. 
 
3.5.4  Clinical validation 
The method was biologically validated by a gonadotropin stimulation test using a synthetic 
analog of GnRH (buserelin acetate) (Receptal, MSD Animal Health, Milan, Italy) in 4 Holstein 
Friesian heifers (15-month-old). The experiment was conducted at the Milan University Centro 
Zootecnico Didattico Sperimentale (Experimental zootechnical teaching station) (Lodi) and met the 
requirements of the Italian and European Community Commission for Scientific Procedures. The 
protocol was approved by the Animal Experimentation Ethics Committee of the State University of 
Milan. Ten days before the experiment, the 4 heifers were given a single intramuscular (i.m.) 
injection of 150 mg of a PGF2alpha analog (d-cloprostenol, Dalmazin, Fatro, Italy) during the luteal 
phase.  
To minimize stress the animals were surgically implanted with an indwelling catheter in the 
jugular vein (Nutricath, Vygon, Ecouen, France). On the day after cannulation, the animals received 
an intravenous (i.v.) bolus injection of the GnRH analog buserelin acetate (20 µg/5 mL saline). Blood 
samples were collected into heparinized tubes starting 75 min before treatment, then every 15 min up 
to 6 h 30 min after treatment. The plasma was centrifuged at 2500 rpm for 10 min, divided and stored 
at -80°C until assayed.  
Basal bLH concentration was calculated as the mean (± standard deviation [SD]) of the blood 
values before GnRH infusion. The start, end, and duration of the secretory peak were calculated as 
described by Merriam (Merriam et al., 1982). The magnitude of the peak was the highest hormone 
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level achieved during the peak. The amplitude was expressed as the fold-increase of the magnitude 
from baseline. The total amount of LH released during the peak was expressed as area under the 
curve (AUC). 
 
3.6  Development and validation of the ELISA for bFSH 
The ELISA for bFSH was carried out substantially as described for bLH, with the difference of 
mAbs and standard used. The first coating was performed adding 1ug/100ul/well of anti-bFSH mAb-
A3C12. bFSH standard and samples were diluted as described for the bLH ELISA. The second 
biotinylated antibody was the anti-α-subunit mAb-D2H1, diluted 1/1000. All the other steps were as 
described for bLH. 
 
3.6.1  Analytical specificity 
The slope of the curve with A3C12-bFSH was compared with the slope of the curves obtained 
using serial dilutions of USDA-bFSH-B1, bovine plasma and bovine pituitary extract. The pituitary 
extract was prepared as previously described (Secchi C., 1988), and assayed starting at the protein 
concentration of 0.2 mg/ml. The experiment was repeated 3 times and parallelism was assessed 
within each experiment using GraphPad PRISM 5.0 software package, as described in (see section 
3.3.1). The percentage of cross-reactivity was calculated on the basis of the ED50 calculated from 
each curve. 
 
3.6.2  Cross-reactivity 
Serial dilutions of bLH (USDA-bLH-B-6) and bTSH (USDA-bTSH-I-1) were tested in the 
ELISA. The hormones were diluted in PBS-T, BSA (0.1%). Cross-reactivity coefficients (%) were 
calculated as the bLH concentration divided by the cross-reactant concentration providing the same 
signal in ELISA. 
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3.6.3  Accuracy and reproducibility 
Graded doses of bFSH standard were added to a bovine plasma with known bFSH content. The 
samples were tested by ELISA and the correlation between the measured and the added 
concentrations was established. Inter-assay coefficient of variation was calculated analyzing one 
bovine plasma sample which had a measurable hormone concentration bovine plasma samples. 
Plasmas were assayed several times in different plates 
 
3.6.4  Clinical validation 
The method was biologically validated using the samples obtained by the gonadotropin 
stimulation test described for bLH clinical validation (see paragraph 3.4.4). 
Basal bFSH concentrations were calculated as the mean (± standard deviation [SD]) of the 
blood values before GnRH infusion. The magnitude of the peaks was the highest hormone level 
achieved during the peak. 
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4.  RESULTS 
 
4.1  Production and characterization of anti-bFSH and anti-bLH mAbs 
About 300 viable hybridomas clones were obtained after immunization with the purified bLH 
and bFSH we obtained in small amount from external laboratories (bLH-USDA-B-6 and bFSH-
Fitzgerald Industries). At a first screening, 17 of these hybridomas resulted reactive to the bLH-
USDA-B-6, and 20 to the Fitzgerald Company’s pituitary bFSH.  
A second screening was performed to assess the cross-reactivity of each produced mAb toward 
bFSH, bLH and bTSH, sharing a common α-subunit (Figure 9). 
 
 
 
 
 
Figure 9 
mAbs specificity measured by direct ELISA. Microtiter plates were coated with USDA-bLH-B-6 
(●), USDA-bFSH-I-2 (○), or USDA-bTSH-I-1 (∆) and serial dilutions of 4 different mAbs were 
added. The bound mAbs were revealed with HRP-conjugated rabbit anti-mouse immunoglobulins. 
The means of triplicate wells in a single experiment are shown. The affinity (Kd) to the specific 
antigen of each mAb is reported in the box below the graph. 
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Two anti-bLH mAbs showed no reactivity to bFSH and bTSH (cross reactivity <0.1%), and 
were thus considered against the β-subunit of bLH. This two mAbs were named anti-bLH mAb-
N6H7 and anti-bLH mAb-N3G8.  
Only one anti-bFSH mAb did not recognize bLH and bTSH (cross reactivity <0.1%), and was 
considered against the β-subunit of bFSH. This mAb was named anti-bFSH mAb-A3C12.  
These three mAbs (N6H7, N3G8 and A3C12) proved to be of the IgG1 k subclass. They were 
therefore subcloned and purified. The affinity to their specific antigens was then measured. The Kd 
were 2.91 nM, 1.01 nM and 0.83 nM for N6H7, N3G8 and A3C12, respectively. 
The remaining mAbs showed 100% cross-reactivity with bLH, bFSH and bTSH. They were 
therefore considered against an epitope located on the common pituitary glycoprotein hormones α-
subunit. Of these α-subunit mAbs, mAb-D2H1 showed the highest reactivity and was therefore 
selected for further evaluation. Anti-α mAb-D2H1 proved to be of the IgG1 k subclass with similar 
affinity to bLH and bFSH (Kd 10.061 nM and 8.86 nM respectively).  
Table 8 shows the results of competition binding analysis of pairs of these four selected mAbs 
(N6H7, N3G8, A3C12, D2H1) to bLH and bFSH by the LACT test. The four mAbs recognized four 
non overlapping epitopes. 
 
 
Table 8 
Competition binding analysis of pairs of mAbs to bLH or to bFSH using the LACT assay. The 
assay involved the displacement of an HRP-labeled mAb (listed in the first row) from 
immobilized bLH or bFSH with increasing concentrations of a second unlabeled mAb (in the left-
hand column). The EC50 of the self-inhibition curve was taken as 100%. 
 
Competing mAb                                                  HRP-mAb (inhibition %) 
 Anti-bLH N6H7 Anti-bLH N3G8 Anti-bFSH A3C12 Anti-αsubunit D2H1 
Anti-bLH N6H7 100.0 9.1 / 6.7 
Anti-bLH N3G8 7.9 100.0 / 3.8 
Anti-bFSH A3C12 / / 100.0 - 
Anti-α subunit D2H1 1 0.2 - 100.0 
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4.2  Purification and characterization of bLH and bFSH 
The key step of the purification procedure was the mAb based immunoaffinity chromatography 
of bovine pituitary extract. The antibodies used to this purpose were the anti-bbLH mAb-N6H7 and 
the anti-bbFSH mAb-A3C12, for purification of bLH and bFSH respectively. 
From 100 g of pituitary homogenate (about 50 pituitary glands), by subsequent precipitation 
steps we firstly recovered two crude extracts: 343.6 mg of crude bLH (bLH-1) and 337.5 mg of crude 
bFSH (bFSH-1).  
These two pituitary extract were then loaded into the two immunoaffinity chromatography 
columns. For every chromatographic run we loaded about 50 mg of bLH-1 or bFSH-1. 
In total, from 100 g of pituitary homogenate we recovered 1.58 mg of purified bLH (N6H7-
bLH) and 400 µg of purified bFSH (A3C12-bFSH). 
 
 
4.3  Characterization of purified A3C12-bFSH and N6H7-bLH 
 
4.3.1  Biological activity 
The biological activity of the purified N6H7-bLH was measured in vitro, using the MA-10 cell 
line. Figure 10 shows the linear regression analysis of progesterone production after 4 h incubation 
with increasing concentration of reference standard USDA-bLH-B-6 and the immunoaffinity purified 
N6H7-bLH.  
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The regression lines were calculated by fitting the points within the linear portion of the log 
transformed dose-response curve (1–25 ng/mL). There was no appreciable difference between the 
slopes and y intercepts of the dose-response lines (P > 0.1). Therefore we concluded that N6H7-bLH 
was as potent as the USDA-bLH-B-6, with specific activity 2.1 U/mg. The ED50 of both curves was 
15.74 ng/ml. The specificity of progesterone production in response to bLH was demonstrated by the 
fact that these cells did not respond to USDA-bFSH-I-2 and USDA-bTSH-I-1 (data not shown). 
The biological activity of A3C12-bFSH was measured in vitro with the FSHR-17 cell line 
(Keren-Tal et al., 1993). Figure 11 shows the linear regression analysis of progesterone production 
after 24 h incubation with increasing concentrations of reference standards USDA-bFSH-I-2 and 
USDA-bFSH-B-1 and the immunoaffinity purified A3C12-bFSH.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 
Linear regression analysis of the dose-related progesterone 
production by MA-10 cells in response to reference preparation 
USDA-bLH-B-6 and N6H7-bLH. Progesterone values are means 
±SD of triplicate cultures from a representative experiment. The 
accumulation of progesterone in the absence of LH is shown by the 
hatched area (control). 
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There was no appreciable difference between the slopes of the lines after log transformation 
(P=0.25, F=1.54). This parallelism indicates the analytical specificity of the FSHR-17 bioassay. On 
comparing the EC50, we found that A3C12-bFSH was about 160 times more potent than USDA-
bFSH-B-1 and 7 times less than USDA-bFSH-I-2 (A3C12-bFSH: EC50=31.3 ng/ml; USDA-bFSH-I-
2: EC50=4.3 ng/ml; and USDA-bFSH-B-1: EC50=5013.4ng/ml). Considering the specific activity of 
the standard USDA-bFSH-I-2 (854 U/mg), the calculated specific activity of A3C12-bFSH was 
117.3 U/mg. The specificity of the progesterone production in response to bFSH was demonstrated 
by the fact that these cells did not respond to USDA-bLH-B-6 and USDA-bTSH-I-1 (data not 
shown).  
 
 
 
 
Figure 11 
Parallelism in the FSHR-17 cell bioassay of the dose–response curves of USDA-
bFSH-I-2 (36, 12, 4, and 1.2 ng/ml), USDA-bFSH-B-1 (21000, 10500, 5250, 
2625, and 1312.5 ng/ml) and A3C12-bFSH (140, 70, 35, 17.5, and 8.7 ng/ml). 
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4.3.2  SDS- electrophoresis (SDS-PAGE) 
In SDS-PAGE, purified N6H7-bLH (Figure 12) showed 2 major bands, both under reducing 
(lane 1) and non-reducing conditions (lane 3). The electrophoresis pattern exactly matched that of 
USDA-bLH-6 (lanes 2 and 4). The calculated molecular weights (Mr) of these bands were 20300 and 
18690 in the reducing gel, and 21980 and 19500 in the non-reducing gel.  
In SDS-PAGE purified A3C12-bFSH (Figure 12), showed only one band under reducing (lane 
5) and two under non-reducing conditions (data not shown). The electrophoresis pattern of A3C12-
bFSH exactly matched that of USDA-bFSH-I-2 (lanes 6). The single band has calculated Mr of 
22358. 
  
 
Figure 12 
SDS-PAGE of purified bLH and bFSH. Hormone samples were electrophoresed on 7% to 
20% gradient polyacrylamide gels under reducing or non-reducing conditions and were 
stained with silver nitrate. Lane 1: N6H7-bLH, after reduction; lane 2: USDA-bLH-6, after 
reduction; lane 3: N6H7-bLH, no reduction; lane 4: USDA-bLH-6, no reduction; lane 5: 
A3C12-bFSH, after reduction; lane 6: USDA-bFSH-I-2 after reduction. Std: Mr wt markers. 
The positions of the molecular-weight markers are indicated. 
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4.3.3  Western blot 
Figure 13 shows the analyses in western blot with different mAbs of the purified N6H7-bLH 
(A and B) and A3C12-bFSH (C and D). Gel A and C were run under reducing conditions, and gel B 
and D under non-reducing conditions. 
The anti-α subunit mAb-D2H1 recognized the bands at: Mr 20300 (lane 1, bLH after 
reduction), Mr 19500 (lane 4, bLH no reduction), Mr 22358 (lane 8, bFSH after reduction), Mr 20771 
(lane 9, bFSH no reduction). The anti-bLHβ mAb-N3G8 recognized the bands at: Mr 18690 (lane 3, 
bLH, after reduction), 21980 (lane 6, bLH no reduction).  
The anti-bFSHβ mAb-A3C12 recognized the bands: at Mr 22358 (lane 7, bFSH, after 
reduction), Mr 27640 (lane 11, bFSH no reduction). 
Lanes 2 and 5 (bLH) were probed with a mixture of the anti-α subunit mAb-D2H1 and anti-
bLHβ mAb-N3G8. Lane 10 with a mixture of the anti-α subunit mAb-D2H1 and anti-bFSHβ mAb-
A3C12. 
In western blotting, the anti-bLHb mAb-N6H7 did not recognize any of the various bLH and 
bFSH bands, analyzed both under reducing and non-reducing conditions. 
These data confirmed the ELISA results (see section 4.1), which indicated that mAb-D2H1 
recognize an epitope on the glycoprotein common α-subunit, and mAb-N3G8 and A3C12 recognize 
epitopes localized on the β-subunit of bLH and bFSH, respectively.  
The western blot data also revealed that the α and the b subunits of bLH when analyzed under 
reducing or non-reducing conditions, inverted their relative positions on the gel. In the non-reducing 
gel the bLHβ-subunit migrated more slowly than the bLHα-subunit, the reverse under reducing 
conditions. As for bLH also bFSH migrated in a different way under reducing and non-reducing 
conditions. Under reducing conditions only a single band for both α- and β-subunit was evident, 
while in the absence of the reducing agent the two subunits migrated in two separate bands. 
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Figure 13 
Western blot immunodetection of N6H7-bLH (gel A and B) and A3C12 b-FSH (gel C and D) in 
reducing (gel A and C) and non-reducing conditions (gel B and D). Gels were electro-transferred 
onto nitrocellulose, and the membrane was probed with anti-α mAb-D2H1, anti-bLHβ mAb-N6H7 
and anti-bFSHβ mAb-A3C12, singly or combined. Lane 1: N6H7-bLH, after reduction, probed 
with anti-α mAb-D2H1; lane 2: N6H7-bLH, after reduction, probed with a mix of anti-α mAb-
D2H1 and anti-bLHβ mAb-N3G8; lane 3: N6H7-bLH, after reduction, probed with anti-bLHβ 
mAb-N3G8; lane 4: N6H7-bLH, no reduction, probed with anti-α mAb-D2H1; lane 5: N6H7-
bLH, no reduction, probed with a mix of anti-α mAb-D2H1 and anti-bLHβ mAb-N3G8; lane 6: 
N6H7-bLH, no reduction, probed with anti-bLHβ mAb-N3G8; lane 7; A3C12-bFSH, after 
reduction, probed with anti-bFSHβ mAb-A3C12; lane 8: A3C12-bFSH, after reduction, probed 
with anti-α mAb-D2H1; lane 9: A3C12-bFSH, no reduction, probed with anti-α mAb-D2H1; lane 
10: A3C12-bFSH, no reduction, probed with a mix of anti-α mAb-D2H1 and anti-bFSHβ mAb-
A3C12; lane 11: A3C12-bFSH, no reduction, probed with anti-bFSHβ mAb-A3C12. Std: Mr wt 
markers. The positions of the molecular-weight markers are indicated. 
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4.3.4  Isoelectric focusing (IEF) 
Figure 14 shows the IEF analysis of N6H7-bLH (lane 1) and A3C12-bFSH (lane 2). The 
patterns show a large number of tight bands with pI ranging from 9.0 to 4.2 and from 8.0 to 4.5 
respectively for N6H7-bLH and A3C12-bFSH, indicating extensive charge heterogeneity. 
 
 
                                              
Figure 14 
Analytical IEF in polyacrylamide gel stained with 
silver nitrate. Lane 1: N6H7-bLH; lane 2: A3C12-
bFSH; Std: standard proteins; pI: Isoelectric points 
of standard proteins. 
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4.3.5  Protein identification  
The two bands of N6H7-bLH obtained in the reducing SDS-PAGE were extracted and 
analyzed by nanoLCES MS/MS. The upper band (Mr 20300) corresponded to the α-bLH subunit, and 
the lower band (Mr 18690) to the β-bLH subunit. Identification was unambiguous and no peptides 
not corresponding to a theoretical trypsin fragment of the bLH were detected. 
   The band of A3C12-bFSH obtained in the reducing SDS-PAGE was electro-blotted unto a 
PVDF membrane, cut and the protein extracted analysed by N-terminal sequencing. The first 10 
amino acids yielded two sequences with an equal molar ratio. All the amino acids of the α-bFSH 
subunit were detected (F19-P19-D15-G18-E13-F8-T16-M5-Q6-G7, where the subscripts indicates the 
pmoles of amino acid for each sequencing cycle), while two residues were missing in the β-bFSH 
subunit sequence (X0-E31-L20-T21-X0-I12-T16-I10-T6-V9, where X indicates an undetected amino acid). 
These gaps were expected, because the first residue in the mature β-bFSH subunit is a C, and the fifth 
is a glycosylated N. Both α- and β- bFSH sequences were obtained free of contamination by other 
amino acids. 
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4.3.6  Amino acid composition 
Table 9 illustrates the amino acid composition measured for the purified N6H7-bLH and 
A3C12-bFSH. The numbers of each amino acid residue are in agreement with the expected bLH and 
bFSH composition (calculated on the α and β subunit complementary DNA sequences). 
 
 
Table 9 
Amino acid composition of purified N6H7-bLH and A3C12-bFSH. Data are Mol/mol of protein, 
mean (±SD) of 5 different preparations 
Amino Acid bLH              
Theoreticala 
N6H7-bLH  bFSH 
Theoreticala 
A3C12-bFSH 
Asp 11 11.9±1.0 15 14.7±0.9 
Ser 14 16.2±1.3 13 12.8±2.4 
Glu 14 14.7±1.2 18 18.1±1.4 
Gly 11 13.7±1.5 9 10.3±2.0 
His 6 4.2±1.1 6 5.9±0.5 
Arg 11 11.4±1.0 8 7.6±1.2 
Thr 16 16.3±1.6 22 21.1±2.2 
Ala 15 18.4±2.8 12 12.7±1.0 
Pro 27 21.3±3.0 12 11.0±1.1 
Cys  22 n.d.b 22 n.d.b 
Tyr 7 6.9±0.6 12 10.9±0.9 
Val 13 14.0±0.9 12 12.9±0.6 
Met 7 5.9±0.5 4 3.6±1.1 
Lys 12 14.8±1.9 16 15.1±0.6 
Ile 7 6.4±0.3 8 7.4±0.6 
Leu 15 14.0±0.7 7 7.6±0.3 
Phe 9 6.7±0.5 8 8.1±0.8 
Trp 0 n.d.b 1 n.d.b 
a Mol/mol of protein based on the bLH- or bFSH- cDNA. 
b n.d, not determined. 
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4.4  Development and validation of the ELISA for bLH 
The combination of anti-bLHb mAb-N6H7 adsorbed to the solid phase and the biotin-labeled 
anti-bLHb mAb-N3G8 was used to develop a sandwich ELISA to measure bLH in bovine plasma. 
All other mAb combinations tested gave poorer analytical performances. 
 
4.4.1  Analytical sensitivity 
The bLH standard curve for the sandwich ELISA with mAb-N6H7 as capturing antibody and 
the labeled mAb-N3G8 to reveal the bound hormone is shown in Figure 15.  
To check for plasma interference with the assay sensitivity, standards were diluted in either 
bovine plasma, which had a virtually undetectable amount of endogenous bLH (± 0.05 ng/ml), or 
PBS-T, BSA (0.1%). There were no significant differences between slopes and y intercepts of the 2 
curves. The standard curve, plotted as T% vs log of ng/ml of bLH, was linear over the range 0.05 to 
2.5 ng/ml. The regression coefficient was r2 = 0.99 and the ED50 (x intercept when y = 50) was 0.27 
ng/ml. The values plotted were the mean of 12 experiments ± SD and the coefficient of variation 
between the slopes was 2.88%. 
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Figure 15 
Standard curve for the sandwich ELISA of bLH, with 
mAb-N6H7 as solid phase antibody and the labeled mAb-
N3G8 to reveal the bound hormone. Standards were 
diluted in PBS-T, BSA (0.1%). Points are plotted as T% 
versus log of ng/ml of the hormone. Each point is the 
mean of 12 experiments ±SD. 
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4.4.2  Analytical specificity  
Dilutions of bovine pituitary extract, plasma and reference USDA-bLH-6 were compared with 
the dose-response curve for N6H7-bLH in this ELISA (Figure 16). There was no significant 
difference between the slopes, after log transformation of the dilutions (P > 0.1). The sandwich 
ELISA showed 99.95% cross-reaction with standard USDA-bLH-6. 
 
 
 
Figure 16 
Regression lines obtained by serial dilution of the N6H7-bLH (●), 
USDA-bLH-6 (○), pituitary extract (■), and plasma from 3 heifers 
(▲, ▼, ♦). Dilutions ranged between 2.5 and 0.05 ng/ml for the two 
bLHs, 0.8 and 0.02 mg/ml for pituitary extract, and 1/5 to 1/50 for 
plasma samples. Points are plotted as T% versus log of ng/ml of 
hormone or ml of plasma and pituitary extract. The means of 
duplicate wells in a representative experiment are shown. 
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4.4.3  Cross-reactivity  
Standard USDA-oLH-I-2 showed 99.5% cross-reactivity. Conversely, no cross-reactivity (≤ 
0.1%) was observed with bFSH and bTSH (Figure 17).  
No reactivity was observed with hCG, horse, dog, pig, rabbit, and mouse pituitary extracts, 
even when assayed at a protein concentration of 8 mg/ml, thus 400-fold higher than the lowest 
concentration of the bovine pituitary extract showing significant reactivity (0.02 mg/ml, Figure 16). 
 
 
 
 
Figure 17 
Cross-reactivity of the sandwich ELISA to bLH (●), oLH (○), 
bTSH (∆), and bFSH (*).  
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4.4.4  Accuracy 
Various amounts of bLH were added to pools of bovine plasma, and the overall recovery was 
summarized in linear regression analysis (Figure 18). Recoveries ranged between 83.2% and 119.3%, 
and the slope of the regression was not different from unit (slope, 1.03 ± 0.01; y-intercept, - 0.04 ± 
0.04; r2 = 0.99, n = 67). 
 
 
 
Figure 18 
Linear regression with recoveries ranging between 83.2% and 
119.3%.  
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4.4.5  Reproducibility 
The intra- and inter-assay coefficients of variation were calculated by measuring the plasma LH 
concentration in 5 heifers (Table 10). Bovine LH concentrations ranged between 0.32 and 1.70 
ng/mL. The intra-assay CV ranged between 3.41% and 9.40% and the inter-assay CV between 9.29% 
and 15.84%. 
 
 
Table 10 
Inter- and intra-assay variability of the ELISA for the detection of bLH in bovine plasma. 
Animal bLH 
ng/ml ± SD 
Inter-assay 
CV (%) 
bLH 
ng/mL ± SD (n) 
Intra-assay CV 
(%) 
1 1.67 ± 0.16 (27) 9.29 1.70 ± 0.09 (15) 5.49 
2 1.54 ± 0.19 (28) 12.23 1.50 ± 0.12 (16) 8.30 
3 1.50 ± 0.24 (28) 15.84 1.43 ± 0.13 (16) 9.40 
4 1.44 ± 0.20 (28) 14.06 1.39 ± 0.05 (16) 3.41 
5 0.35 ± 0.05 (31) 14.68 0.32 ± 0.03 (12) 8.99 
Abbreviations: (n), number of determinations; SD, standard deviation 
 
 
 
4.4.6  Clinical validation 
The analytical specificity of the method was confirmed by stimulation tests for LH using GnRH (20 
µg) in 4 heifers. As expected, plasma bLH rose significantly in all animals shortly after the injection 
(Figure 18), with some differences in the LH surge (Table 11). In general, plasma LH started to rise 
between 30 and 75 min after injection, reaching a peak at 120 to 150 min, and rapidly declined to 
pretreatment levels by 225 to 255 min. Intravenous injection of 5 ml saline did not change plasma LH 
levels throughout the test period. 
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Figure 18 
Plasma bLH patterns after injection of GnRH (20 mg, arrows) in 4 heifers. The 
horizontal line indicates the individual baseline bLH concentrations calculated as 
the means before GnRH. 
 
 
 
 
Table 11 
Individual baseline bLH concentrations and GnRH-induced peaks in 4 heifers. 
Heifer 
No 
Baseline 
(ng/ml) 
GnRH  induced bLH response    
  Start (min) Stop Duration Magnitude Amplitude AUCa 
   (min) (h:m) Time 
(min) 
Level  
(ng/ml) 
(fold 
increase) 
(ng/ml) 
1 0.22 ± 0.05 30 255 3:45 135 4.32 20 29.60 
2 0.28 ± 0.05 75 255 3:00 150 2.16 8 15.10 
3 0.59 ± 0.07 60 255 2:45 120 4.03 7 27.33 
4 0.17 ± 0.05 45 240 3:15 150 2.98 18 18.70 
aAUC, area under the curve;  
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4.5  Development and validation of the ELISA for bFSH 
The combination of the anti-bFSHβ mAb-A3C12 adsorbed to the solid phase and the biotin-
labeled anti-α subunit mAb-D2H1 was used to develop a sandwich ELISA to measure bFSH in 
bovine plasma.  
 
4.5.1  Analytical sensitivity 
The bFSH standard curve for the sandwich ELISA with mAb-A3C12 as capturing antibody and 
the labeled mAb-D2H1 to reveal the bound hormone is shown in Figure 19. To check for plasma 
interference with the assay sensitivity, standards were diluted in either bovine plasma, which had a 
virtually undetectable amount of endogenous bFSH, or PBS-T, BSA (0.1%). There were no 
significant differences between slopes and y intercepts of the 2 curves. The standard curve, plotted as 
T% vs log of ng/ml of FSH, was linear over the range 0.25 to 10 ng/ml. The regression coefficient 
was r2 = 0.97 and the ED50 (x intercept when y = 50) was 1.65 ng/ml. The values plotted were the 
mean of 14 experiments ± SD and the coefficient of variation between the slopes was 3.51%. 
Figure 19 
Standard curve for the sandwich ELISA of bFSH, with mAb-
A3C12 as solid phase antibody and the labeled mAb-D2H1 to 
reveal the bound hormone. Standards were diluted in PBS-T, 
BSA (0.1%). Points are plotted as T% versus log of ng/mL of 
the hormone. Each point is the mean of 14 experiments ±SD.  
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4.5.2  Analytical specificity  
Dilutions of reference standard USDA-bFSH-I-2, bovine pituitary extract and plasma were 
compared with the dose-response curve for purified A3C12-bFSH in ELISA (Figure 20).  
There was no significant difference between the slopes, after log transformation of the dilutions 
(P > 0.1). The sandwich ELISA showed 84.7% cross-reaction with standard USDA-bFSH-I-2 . 
 
  
Figure 20 
Regression lines obtained by serial dilution of theA3C12-bFSH 
(▲), reference standard USDA-bFSH-B-1 (■), pituitary extract 
(●), and plasma from 2 heifers (□, ○). Dilutions ranged between 
0.25 and 10 ng/ml for A3C12 bFSH and USDAbFSH-B-1, 0.2 
and 0.0002 mg/ml for pituitary extract, and 1/1 to 1/100 for 
plasma samples. Points are plotted as T% versus log of ng/ml of 
hormone or ml of plasma and pituitary extract. The means of 
duplicate wells in a representative experiment are shown. 
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4.5.3  Cross-reactivity 
No cross-reactivity (≤ 0.1%) was observed with bTSH and bLH (Figure 21), even though these 
three hormones share the same α-subunit and similar tridimensional structure.  
 
 
                                               
Figure 21 
Cross-reactivity of the bFSH sandwich ELISA to bFSH 
(●), bTSH (○) and bLH (▲). 
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4.5.4  Accuracy 
Various amounts of bFSH were added to pools of bovine plasma, and the overall recovery was 
summarized in linear regression analysis (Figure 22).  
Recoveries ranged between 69.6% and 129.7%, with regression values: slope 0.77 ± 0.04; y-
intercept, 0.39 ± 0.19; r2 = 0.97; n = 14. 
 
Figure 22 
Linerar regression with recoveries ranging between 
69.6% and 129.7%. 
 
 
 
4.5.5  Reproducibility 
The inter-assay coefficients of variation was calculated by measuring the bFSH concentration 
in a bovine plasma. bFSH concentration was 1.51 ng/ml ± 0.21 (SD) (n=15) with the inter-assay CV 
of 13.79%. 
  
65 
 
 
4.5.6  Clinical validation 
Figure 23 shows the bFSH plasma patterns measured in four heifers, before and after GnRH 
stimulation. Secretion of bFSH was clearly pulsatile, and no clear secretory peak was evident after 
GnRH injection. Plasma hormone peaks were irregularly distributed throughout the 8h of plasma 
collection, were of variable length (15-60 min) and of small amplitude and magnitude.  
 
Figure 23 
Plasma bFSH pattern after injection of GnRH (20 mg, arrows) in 4 heifers. The horizontal line 
indicates the individual baseline bFSH concentrations calculated as the means before GnRH. 
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5.  DISCUSSION 
Maximizing livestock reproductive potential is of primary importance in business farming, and 
it’s the reason for the increasing interest in the development as well as the application of innovative 
bio-techniques addressed to the improvement of in vivo and in vitro farm animal fertility. Most of the 
achievement in this field relies on the knowledge of the complex mechanisms involved in the control 
of follicular growth, oocyte maturation and early embryonic development. Pivot molecules regulating 
these aspects of animal reproduction are the pituitary gonadotropins. Methods able to study FSH and 
LH plasma patterns in the bovine species have therefore implications in improving cattle 
reproductive efficiency, for example by helping detection of dysfunction of the pituitary-ovarian axis, 
diagnosis of reproductive disorders, monitoring of antifertility programs and monitoring endocrine 
therapy. 
However, the determination of gonadotropins in bovine plasma by immunoassay it’s not 
straightforward. It rely on in-house validated methods, developed by specialized laboratories with 
species-specific reagents which are provided in small quantity by International Institutions (e.g. 
USDA). In fact a bottle neck step for the development and large-scale application of bLH and bFSH 
immunoassays is the limited supply of pure bLH and bFSH to be used as immunogen and/or 
reference standard. 
In the present PhD thesis we describe the production of a panel of anti-bLH and anti-bFSH 
mAbs and their successful application in the immunoaffinity purification of bLH and bFSH from 
pituitary glands. These reagents were then combined for the development of new homologous, 
specific, sensitive, and reproducible sandwich ELISAs for the measurement of the two gonadotropins 
in bovine plasma. 
For the production of the mAbs against pituitary gonadotropins, we firstly requested small 
amounts of purified bLH and bFSH provided by international institutes. We then used these standard 
hormones as immunogens, to obtain a panel of species-specific anti-bLH and anti-bFSH mAbs. 
While monoclonal antibodies against human gonadotropins are widely available, in literature there 
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are only few reports on the production and characterization of mAbs to bovine FSH and LH. 
Specifically, two reports on the production of anti-bLH mAbs (Matteri et al., 1987; Kofler et al., 
1981) and two on the development of anti-bFSH mAbs (Miller et al., 1987; Zou et al., 1991). 
Furthermore, to the best of our knowledge, no mAbs nor hybridoma clones to bovine gonadotropins 
are commercially available. 
Among more than 300 hybridoma clones produced, we selected two clones secreting mAbs 
recognizing with high affinity two non-overlapping epitopes on the β-subunit of the bLH molecule 
(mAb-N3G8 and mAb-N6H7), one clone producing mAbs to an epitope localized on the β-subunit of 
the bFSH molecule (mAb-A3C12), and one clone secreting mAbs binding to the pituitary 
glycoprotein common α-subunit (mAb-D2H1). These epitopes were localized firstly by testing the 
cross-reactivity of each mAb toward bLH, bFSH and bTSH: mAbs reacting with the β-subunit of one 
hormone did not cross-react with the other hormones, while mAbs binding to the α-subunit bound to 
the three bovine pituitary glycoprotein hormones with the same affinity. Second, by testing the ability 
of mAbs to recognize the specific subunits in immunoblotting. In fact, in SDS-PAGE, the subunits of 
bLH and bFSH migrated separately.  
Immunoblotting analyses also allowed to acquire some information about the nature of the 
epitopes. We suggest that anti-bLHb mAb-N3G8, anti-bFSHb mAb-A3C12 and anti-α subunit mAb-
D2H1 bind to stable epitopes, while anti-bLHb mAb-N6H7 is conformation sensitive. In fact, mAbs 
N3G8, A3C12 and D2H1, but not N6H7, recognized the separate subunits even when the protein 
conformation was altered, as in SDS-PAGE after disulphide bridge reduction. Anti-bLHb mAb-
N6H7 might possibly recognize an epitope on the conformationally intact β subunit or a structure that 
is only expressed in the holo-hormone but not in the free subunits. Further studies using isolated bLH 
subunits are needed to confirm this. 
In general, mAbs recognizing denatured hormones, such as N3G8, A3C12 and D2H1, might 
have other applications besides their use for hormone subunit detection after blotting, such as 
immuno-histochemical investigations. Conformation sensitive antibodies such as N6H7 could be 
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used to study the changes in pituitary bLH during purification, to verify the appropriate folding of the 
hormone produced by recombinant technology, and to check artefactual changes during storage 
(Borromeo et al., 2003). 
The ability of anti-bLHb mAb-N6H7 and of anti-bFSHb mAb-A3C12 to bind with high 
affinity to the hormones was exploited in 1-step purification by immunoaffinity chromatography of 
substantial amount of biologically active bLH and bFSH, respectively. 
Immunoaffinity-chromatography has already been used to purify bFSH either from pituitary 
extracts (Miller et al., 1987), or produced by recombinant technology (Dirnberger et al., 2001; Van 
De Wiel et al., 1998), while to the best of our knowledge this is the first time that it has been used for 
bLH purification. 
The two purification procedures developed were rapid and easy, allowing the one-step recovery 
of about 4 mg of bFSH and 16 mg of bLH from 1 kg of pituitary gland homogenate. Nevertheless, 
the purification yields are somewhat poorer of those previously reported by other authors that used 
different purification methods. The yields of bLH recoveries are in fact lower than that of multistep 
extraction procedures from fresh glands described by Reichert (60 mg/kg) (Reichert et al., 1962), 
Courte (170 mg/kg) (Courte et al., 1972), and Papkoff (90 mg/kg) (Papkoff et al., 1970). As well, the 
yields of bFSH are lower than Miller’s figures (22.2 mg/kg) (Grimek et al., 1979; Miller et al., 1987; 
Wu et al., 1993), and similar to what was obtained by Wu (1.7, 2.5, and 1.5mg/kg for three different 
bFSH isoforms), and Grimek (1.3 mg/kg). 
The low column capacity was not the reason of the relatively low efficiency shown by our bLH 
and bFSH purification methods. In fact, despite the rather low bLH and bFSH binding capacity of our 
immunoaffinity columns (i.e. about 230 mg, compared to a theoretical capacity of about 1 mg of bLH 
or bFSH, on a 1:1 molar ratio with 10 mg of mAb coupled to the column), the procedure was carried 
out without exceeding the column binding capacity. In fact in preliminary experiments, we loaded 
onto the column increasing amount of pituitary extracts (25-200 mg), and we selected the 50 mg dose 
because the pure bLH or bFSH eluted from the columns did not increased significantly using greater 
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pituitary extract amounts (> 60-70 mg). Furthermore, the bLH or bFSH eluted from a second 
chromatographic run in which the unbound fraction was loaded onto the column, became significant 
when the extract dose was higher than 50 mg. We therefore considered 50 mg of pituitary extracts as 
the maximum loading capacity of our columns.  
We are now examining ways of improving the bLH and bFSH recoveries of our 
immunoaffinity chromatography procedure. However, modifying the elution buffer (e.g., lower pH in 
the presence of 6 M guanidine) only minimally improved recovery, and significantly reduced their 
biological activity. In fact, bovine gonadotropin dissociation into subunits is greatly facilitated by pH 
below 4 or in the presence of a denaturant such as 6 M guanidine hydrochloride (Sairam, 1991; 
Gospodarowicz,1972). The yield was also not improved by loading the column with partially purified 
pituitary extract, or by coupling other anti-β subunits mAb to the affinity column (data not shown).  
The immune-purified bLH and bFSH both showed high biological activity. That of N6H7-bLH 
was equal to that of reference USDA-bLH-B-6 (2.1 U/mg), and equivalent to that of bLH from 
pituitary glands purified by other authors: the first purified bLH had specific activity of 1.69 U/mg 
(Reichert et al., 1962), Papkoff purified a bLH with biological activity of 1.5 U/mg (Papkoff et al., 
1970), and Courte achieved 2 U/mg (Courte et al., 1972). 
The biological activity of the purified A3C12-bFSH was 91.8 U/mg, which is 7 times less than 
that of reference bFSH-USDA-I-2, but 160 times more potent than that of standard bFSH-USDA-B-
1. Furthermore, this bio-potency is comparable to that reported previously for other pituitary purified 
bFSH: Grimek (43.0 U/mg) (Grimek et al., 1979) and Wu (217.0, 86.0, and 62.0 U/mg for three 
different bFSH isoforms) (Wu et al., 1993).  
In general it is difficult to compare the specific activity of bFSH and bLH purified in different 
laboratories. Quantification of the activity of FSH and LH mostly depends on the bioassay and 
standard chosen (Christin-Maitre et al.., 1996; Kalia, 2004; Rose et al., 2000; Ulloa-Aguirre et al., 
2003) and reliable comparison is further complicated for the results of in vitro and in vivo bioassays 
(Christin-Maitre et al., 1996).  
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For testing the biological activity of bFSH, we used the in vitro FSHR-17 cells, that allowed 
sensitive, reproducible and specific measurment of bFSH biological activity. The sensitivity of this 
bioassay is one order of magnitude lower than in the classical primary Sertoli cell bioassay (Ritzen et 
al., 1982), but much better than that of other bioassays based on cloned receptors (Albanese et al., 
1994; Christin-Maitre et al., 1996; Dirnberger et al., 2001; Van De Wiel et al., 1998). Expression of 
the rat instead of the human FSH receptor (FSHR) on the FSHR-17 cells may be one reason 
accounting for the higher sensitivity of this recombinant bioassay for the bovine hormone. In fact, 
ruminant FSH was shown to have higher affinity to rat than to human FSHR (Tilly et al., 1992). 
For testing the biological activity of bLH we used the MA-10 cell line, that is a well-
established assay to measure LH activity (Zhou et al., 2013; Dahl K.D., 1993). Nonetheless, it has 
never been used before to quantify the biological activity of bLH in terms of U/mg. The bLH dose-
response curves obtained with this bioassay in our experiments were very similar to those reported by 
others using different standard USDA-bLH preparations (i.e.: ED50 in the 10–20 ng/mL range) (Dahl 
K.D., 1993; Smith et al., 1990). This confirms that the bLH we purified has a biological activity 
equivalent to the reference USDA-bLH independently of the U/mg calculated and the assay used. 
In SDS-PAGE the bLH α- and β-subunits migrated as two separate bands, under reducing and 
non-reducing conditions. This was expected, since the subunits of gonadotropins promptly dissociate 
after boiling in the presence of SDS (Reichert et al., 1973; Parsons et al.,1985; Bousfield et al., 
1996). After reduction, the β-subunit showed greater electrophoretic mobility than the α-subunit (β-
subunit: Mr 18690; α-subunit: Mr 20300), while in absence of the reducing agent, the β-subunit 
migrated more slowly than the α-subunit (β-subunit: Mr 21980; α-subunit: Mr 19500). This 
anomalous behavior is consistent with previous reports, showing that under non-reducing conditions 
the α-subunit migrates more than the bLH β-subunit (Reichert et al., 1973), and the reverse is true 
under reducing conditions (Reichert et al., 1973; Bousfield et al., 1996).  
Taking into account that (1) the bLH β-subunit is 25 residues longer than the α-subunit, but 
possesses only a single N-linked oligosaccharide (Asn13) whereas the latter has 2 (Asn56 and Asn82); 
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and that (2) bLH is a disulphide-rich heterodimer, with a cysteine-knot motif in the central core of 
each subunit (Jiang et al., 2014), it is reasonable to hypothesize that upon reduction, the subunits 
folding and the sugar chain display is so greatly altered that it overturns the SDS-PAGE migration. 
In SDS-PAGE under reducing conditions the purified bFSH showed a single band, at Mr 
22358, while in the absence of the reducing agent, the bFSH α- and β-subunits migrated as two 
separate bands (α-subunit: 20771; β-subunit: 27640). The slower migration of the α- compared to the 
bFSH β-subunit in non-reducing conditions is consistent with the fact that both subunit have two N-
linked oligosaccharides, but the β-subunit is 13 residues longer. The finding that the two subunits 
after reduction had the same SDS-PAGE mobility is less evident. We can hypothesize that, as for 
bLH subunits, breaking the cysteine-knot core of the bFSH subunits alter the protein folding and 
sugar chain display so much to distort the apparent Mr.  
In IEF the immunopurified bFSH and bLH revealed extensive charge heterogeneity, indicating 
the presence of a wide array of differently glycosylated isoforms. In fact, it is well known that sugars 
form the major chemical basis of heterogeneity of gonadotropins in pituitary and the bloodstream in 
many animal species, including bovines (Perrera-Marin et al., 2008; Baenziger et al., 1988). The 
fact that the two gonadotropins were purified from a pool of unselected bovine pituitaries, regardless 
to sex, physiological status and age, might have increased the heterogeneity. In fact glycoprotein 
hormones are known to exist in the pituitary as a dynamic population of isoforms that exhibit 
changes in relative abundance reflecting the endocrine status of the individual (Cooke et al., 1997; 
Padmanabhan et al., 1999; Rose et al., 2000; Ulloa-Aguirre et al., 2003).  
The possibility exists that the immuno-purification procedure has missed some of the bLH and 
bFSH differently glycosylated isoforms present in the pituitary extract, because not recognized by the 
anti-bLH or anti-bFSH mAb bound to the solid phase. However, contemporary research points to a 
minor role of sugar in glycoprotein hormones antigen structure (Fox et al., 2001; Rose et al., 2000), 
and mAbs routinely used to detect hFSH in biological samples are considered to be almost blind to 
variations in glycosylation (Jeffcoate, 1993). Nevertheless, it is of relevance the report of mAbs that 
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can indeed distinguish between native and desialylated hCG (Rose et al., 2000; Simoni et al., 1994). 
Studies in our laboratory are currently underway to investigate whether binding is affected by the 
bFSH/bLH N-linked oligosaccharides. 
The amino acid sequence and composition analysis of the purified bLH and bFSH showed that 
the polypeptide chain of both hormones was highly homogeneous, suggesting that amino acid 
modifications do not contribute to isoform differences and that the oligosaccharides chains are the 
only source of extensive charge heterogeneity shown in IEF. 
The highly purified bioactive bLH and bFSH were combined with anti-bFSH and anti-bLH 
mAbs to develop sensitive, specific and reproducible sandwich ELISA to measure bLH and bFSH in 
bovine plasma. We selected the best pair to develop sandwich ELISA among more than 300 
hybridoma clones. It is important to develop a library of a sufficient number of different mAbs, to 
improve the likelihood of identifying combinations of antibodies capable of recognizing many forms 
of hormones in biological fluids. This is an existing problem for the detection of human 
gonadotropins (Rose et al., 1998; Costagliola et al. 1994). For example in humans more than 30 
different assays are now available for LH and FSH, but numerous publications have highlighted that 
caution should be still exercised in interpreting assay results. Variations among kits are such that 
coefficients of variation (CV) of 30% or more have been observed. This is claimed to be primarily 
caused by differences in specificity or affinity of different antibodies. 
For the development of the ELISA to determine bLH in bovine plasma we selected the 
combination of anti-βbLH mAb-N6H7 adsorbed to the solid phase and the biotin labeled anti-βbLH 
mAb-N3G8. The ELISA based on these two mAbs allowed the detection of bLH concentrations as 
low as 0.05 ng/mL. The sensitivity is similar to or better than with other bLH ELISAs (Abdul-Ahad et 
al., 1987; Spearow et al., 1987; Mutayoba et al., 1990; Schneider et al., 2002) and 
radioimmunoassay (Niswender et al.,1969; Wolfe et al., 1992; Evans et al., 1992;Schneider et al., 
2002; Perry et al., 2008; Hannan et al., 2010), previously used successfully to detect bLH plasma 
patterns. 
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Plasma components did not interfere with the assay (parallelism and recovery tests), which 
means it is suitable for measuring bLH without any prior treatment of samples. Furthermore, the 
parallelism between serial dilutions of crude pituitary extract, plasma, and the purified bLH suggests 
that the latter was not only pure, as discussed previously, but also was not damaged during the 
purification procedure, at least with regard to its immunoreactivity.  
The precision of the assay, shown by the intra- and inter-assay statistical quality control, 
appears to be acceptable in relation to other methods for LH determination in bovine and other 
species (Kalia., 2004).  
The bLH ELISA developed is species-specific. We tested the reactivity of LH from various 
species, and only ovine LH showed high cross-reactivity. The LH sequences in these two ruminants 
differ only in the substitution of one amino acid in the β subunit (Pro39 vs Leu39). The 100% cross-
reactivity of oLH was therefore expected and confirms previous reports (Niswender et al., 1969; 
Spearow et al., 1987; Valares et al., 2007). Further studies are needed to test the precision and 
accuracy of this ELISA for detection of LH in ovine plasma.  
No reactivity was observed with horse, dog, pig, rabbit, and mouse pituitary extracts. This was 
somewhat unexpected. The bLHβ- subunit amino acid sequence is closely homologous to that of all 
the other species tested (Figure 6). Furthermore, previous studies showed that anti-bLH antibodies 
might have broad species-specificity, reacting to LH from diverse species (Kofler et al., 1981; 
Matteri et al., 1987). Nonetheless, there are a few amino acid sequences in the bovine LHβ that are 
species-specific (eg, b40-b60 and the C-terminal end), clearly distinguishing sheep and cattle from 
non-ruminant species (Wallis, 2001). Furthermore, these sequences seem to be “hot spots” where 
gonadotropin epitopes cluster in antigenic domains (Berger et al., 1996). The absence of cross-
reactivity in our ELISA to horse, dog, pig, rabbit, and mouse LH needs to be confirmed using 
purified LH, but it suggests that one or both mAbs used recognize epitopes not conserved among 
these species LHb subunits. 
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The analytical specificity of the method was confirmed by the capacity to detect plasma LH 
levels in heifers under conditions known to affect LH secretion (Pawson et al., 2005; Fields et al., 
2009). The stimulation of bLH secretion by GnRH was clearly detectable, with an induced pattern of 
circulating LH concentrations similar to that reported in the bovine species by many other authors 
(Bolt et al., 1990; Chenault et al., 1990; Gong et al., 1995; Schneider et al., 2002; Atkins et al., 
2008; Colazo et al., 2009; Rantala et al., 2009; Ginther et al., 2012). The bLH plasma patterns 
induced by i.v. injection of GnRH were similar to those previously obtained using the same route of 
administration (Perrera-Marin et al., 2005), but, unexpectedly also to those reported after i.m. GnRH 
treatment (Golter et la.,1973; Chenault et al., 1990; Atkins et al., 2008; Rantala et al.,2009; Ginther 
et al., 2012). We cannot rationalize why in the bovine the GnRH can induce a bLH release with 
similar pattern after i.m. and i.v. administration. Nevertheless, it is well known that comparing the 
effects of GnRH treatment is a very challenging goal because of the fact that many variables beside 
route of injection affect secretory bLH response (Chenault et al., 1990; Schneider et al., 2002; Atkins 
et al., 2008; Rantala et al., 2009; Colazo et al., 2009). In particular variation among GnRH products 
and doses, circulating steroid hormone milieu at the time of treatment (e.g.: estrous cycle phase), 
bLH assay method, number and timing of blood samples, parameters used to analyze the secretory 
pattern. 
Among these variables, we believe that animal category and high P4 plasma concentrations at 
the time of GnRH treatment may also explain why we found GnRH stimulated bLH peaks with 
magnitude and amplitude smaller than that reported by other authors (Perrera-Marin et al., 2005; 
Atkins et al., 2008; Colazo et al.,2009). In fact, bLH secretion was stimulated with a GnRH analog at 
dose that as reported by Chenault (Chenault et al., 1990) is the most potent in releasing LH in the 
bovine compared to other products. However, we treated young heifers, and the GnRH-induced LH 
release has been shown to be reduced in heifers compared to cows (Lucy., 1986; Atkins et al., 2008). 
Furthermore, the animals were in diestrous, and during the luteal phase of the estrous cycle, when 
circulating P4 concentrations are high, the number of GnRH receptors on the pituitary cells are 
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decreased, which significantly lower the magnitude of the GnRH-induced LH surge in ruminants 
(Giordano et al., 2012; Colazo et al., 2008; Atkins et al., 2008). In general, cows with P4 
concentrations greater than 1 ng/ml had low total LH secretion and LH peak below 5 ng/ml compared 
with cows with lower P4 concentrations. We did not measure P4 levels in our animals, but we trust 
that the heifers had high plasma P4 concentration since the GnRH treatment was done 10 days after a 
PGF2α treatment, and the presence of the corpus luteum was verified by transvaginal 
ultrasonography. The fact that the animals were in the lutein phase is also consistent with the low and 
stable bLH concentrations measured before GnRH administration (Giordano et al., 2012; Colazo et 
al., 2009; Rantala et al., 2009; Atkins et al., 2008; Perera-Marin et al., 2005). 
For the development of the ELISA system to determine bFSH in bovine plasma we selected the 
combination of anti-βbLH mAb-A3C12 adsorbed to the solid phase and the biotin labeled anti-α-
subunit mAb-D2H1.  
In literature several RIA for bFSH have been described (Table 7), but to the best of our 
knowledge, only Prakash (Prakash et al. 1999) and Zou (Zou et al. 1991) described the development 
of ELISAs for bFSH. The assay developed by Zou is, like our ELISA, a mAb based species-specific 
assay, but while the method has proved useful for measuring FSH concentrations in tissue culture 
media and extracts, it was inadequate for analyzing plasma samples, due to insufficient detection 
limit (i.e.: 1 ng/mL). 
The sandwich ELISA we developed was specific and reproducible. No cross-reactivity was 
measurable with other bovine glycoprotein hormones (bLH and bTSH), and plasma components did 
not interfere with the assay (parallelism and recovery tests), confirming the accuracy of the assay for 
measuring bFSH without any prior treatment of samples. The inter-assay statistical quality control 
were similar to that of other methods for FSH determination (Adams et al., 1992-A (9%); Adams et 
al., 1992-B (15%); Cupp et al., 1995 (9.6%); Gong et al., 1995 (8.4%)). 
The ELISA resulted rather sensitive, allowing the detection of bFSH plasma levels as low as 
0.25 ng/mL. This detection limit is similar to that of the ELISA described by Prakash (Prakash et al., 
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1999) and of several RIAs, but is one order of magnitude higher than that of other RIAs for bFSH 
(Palhao et al; 2009; Lane et al., 2008). Experiments are currently underway to improve the 
sensitivity of our assay. In fact, while LH appears to be released in a clear pulsatile manner with large 
secretory burst, the release of FSH is relatively smooth and stable, with small variations respect to 
basal plasma levels. Therefore, more sensitive is the assay, the better it can unravel the pulse 
frequency dynamics of plasma FSH. 
 Nevertheless, the sensitivity of the bFSH assay resulted suitable to detect plasma bFSH levels 
in vivo, as shown by the hormone patterns measured in heifers after GnRH stimulation. Variations of 
bFSH levels were clearly detectable in the plasma of all the four heifers tested, with irregular peaks 
of variable duration and small amplitude and magnitude. This is consistent with the minor bFSH 
surges described in bovine during luteal phase (Edwards et al. 2013; Ginther et al., 2014). As well, 
the absence of a well-defined secretory peak after GnRH injection agree with the current view that 
FSH release is only associated with a small proportion of the GnRH pulses. The majority of FSH 
secretion occurs in fact independently of signals arising from the GnRH receptor to the release 
mechanisms. Thus, GnRH is crucial for the activation of FSH gene, but minimally controls the 
pulsatile secretion of FSH episodes of secretion (Pawson el al., 2005; Padmanabhan et al., 1997; 
Clarke et al., 2002; Kile et al., 1994). 
It should be mentioned that few other studies reported a significant bFSH increase over basal 
levels within 15 min after GnRH administration, reaching maximum peak concentrations 
approximately after 1-2h from treatment (Gong et al., 1995; Gong et al., 1996; Peters et al., 1985). 
This bFSH induced secretory pattern is therefore very similar to that of bLH after GnRH 
administration. To measure plasma bFSH the mentioned authors used well-established RIAs, but a 
cross-reactivity of these RIAs with bLH could rationalize this finding. Nonetheless, as discussed 
above, comparing the effects of GnRH treatment is difficult, because of the many variables that affect 
secretory gonadotropin response (e.g.: experimental protocol, estrus cycle phase, ecc…). 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In the present PhD thesis we describe the production of a panel of anti-bLH and anti-bFSH 
mAbs and their successful application in the development of: (1) alternative methods for the 
purification of LH and FSH from bovine pituitary glands, and (2) sandwich ELISAs to measure these 
two gonadotropins in bovine plasma. 
The mAb-based immunoaffinity chromatography protocols adopted allowed the one-step 
purification of substantial amount of biologically active bLH and bFSH. These methods, besides 
being simple and rapid, appear to have a major advantage over classic methods (e.g.: ion exchange): 
the effect of charge on the separation is minimal. Since LH, TSH and FSH isoforms have similar 
structures and overlapping charge, their separation by methods based acid-base separation is difficult 
and often lead to the selection of specific isoforms, and to the recovery of small amount of hormone 
devoid of most of the original heterogeneity. Conversely, the bFSH and bLH we purified by 
immunoaffinity chromatography consist of a complex mixture of differently glycosylated isoforms. 
Our knowledge of the structure-function relationships and of the endocrine mechanisms 
regulating FSH and LH glycosylation is still limited. In order to assign distinct functional properties 
to defined structural isoforms, information on the respective structures is required. Chemical and 
biochemical characterization, however, are often impeded by the small amounts of sample available, 
thus necessitating extremely highly sensitive and efficient methods of investigation. We trust that the 
immunoaffinity purified bFSH and bLH are a good starting material to isolate differently 
glycosylated isohormones in sufficient amount for detailed functional and structural characterization 
The two homologous, specific, sensitive, and reproducible sandwich ELISAs developed satisfy 
all the criteria required to investigate LH and FSH secretory patterns in the bovine species. Both 
capture and detection antibodies are produced taking advantage of hybridoma cell lines, that produce 
antibodies in unlimited quantities. This guarantee the almost unlimited availability of reagents for 
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such ELISAs and can ensure their long-term continuity in large-scale operation. These methods can 
therefore be useful for rapid, inexpensive and quantitative measurement of the hormone in the pursuit 
of knowledge concerning the reproductive physiology of the bovine species. Understanding of 
gonadotropin-secretory regulation is also important from the Veterinary practical point of view, for 
example in treatment of acyclicity and in improving the superovulatory responses for embryo 
transfer.  
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